PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 0 
Confidential  
  
 
 
A Study  of Crenolanib and Chemotherapy with Cytarabine 
and Anthracyclines in Patients with Newly Diagnosed Acute 
Myeloid Leukemia with FLT3 Activating Mutations  
 
PROTOCOL ARO -006 
 
VERSION 2.0 
 
Date: January 4, [ADDRESS_661908]  
DALLAS TX [ZIP_CODE]  
 
 
 
The information contained in this protocol is confidential and is intended for the use of clinical 
investigators.  It is the property of AROG Pharmaceuticals, Inc., or its subsidiaries and should 
not be copi[INVESTIGATOR_511752] 
(AR-868,596), unless such persons are bound by a confidentiality agreement with AROG 
Pharmaceuticals, Inc., or its subsidiaries.  
 
  

PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 1 
Confidential  
 SIGNATURE [CONTACT_511829]:  
I approve the design of the clinical trial.  
 
__________________________________  _______________________________  
Signature       [CONTACT_391529], academic degree  Vinay Jain, MD  
    Chief Executive Officer  
Institution    Arog Pharmaceuticals, Inc.  
Address    [ADDRESS_661909],  Dallas, TX [ZIP_CODE]  
Telephone number   [PHONE_10630]  
Fax number    [PHONE_10631]  
E-mail address    [EMAIL_9720]  
 
 
 
  
PROTOCOL: ARO -[ADDRESS_661910] of the trial at this site and affirm that:  
 
 I understand and will conduct the trial according to the clinical trial protocol, any approved protocol 
amendments, ICH Good Clinical Practice (ICH Topic E6 GCP) and all applicable Health Authority 
requirements and national laws.  
 I will not d eviate from the clinical trial protocol without prior written permission from the Sponsor and 
prior review and written approval from the Institutional Review Board or Independent Ethics Committee, 
except where necessary to prevent immediate danger to the s ubject.  
 I understand that some Health Authorities require the Sponsors of clinical trials to obtain and supply, when 
required, details about the Investigators’ ownership interests in the Sponsor or Investigational Medicinal 
Product and information regardin g any financial ties with the Sponsor.  
 The Sponsor will use any such information that is collected solely for the purpose of complying with the 
regulatory requirements. I therefore agree to supply the Sponsor with any necessary information regarding 
owner ship interest and financial ties (including those of my spouse and dependent children), and to provide 
updates as necessary.  
 
__________________________________  ____________________________  
Signature       [CONTACT_511830], academic qualifications    ____________________________  
Position (job title)      ____________________________  
Address of Institution      ____________________________  
Phone  and fax      ____________________________  
E-mail        ____________________________  
 
 
 
 
  
PROTOCOL: ARO -[ADDRESS_661911] KIT  ................................ ................................ ..................  17 
5.3. Synergistic activity of crenolanib in combination with cytarabine  ................................ .................  18 
5.4. Antileukemic activity of crenolanib in combination with daunorubicin  ................................ .........  19 
5.5. Clinical studies of crenolanib in AML  ................................ ................................ ............................  19 
5.5.1.  Clinical summary of crenolanib in relapsed/re fractory FLT3 mutated AML  ...................  [ADDRESS_661912] ELIGIBILITY  ................................ ................................ ................................ ..............................  23 
7.1. Inclusion Criteria  ................................ ................................ ................................ ............................  23 
7.2. Exclusion Criteria  ................................ ................................ ................................ ...........................  23 
7.3. Protocol Registration ................................ ................................ ................................ .......................  24 
7.4. Discontinuations  ................................ ................................ ................................ .............................  24 
7.4.1.  Discontinuations of Study Drugs and Disease status/Survival Follow up of Patients  ...... 24 
7.4.2.  Discontinuation of Study Sites  ................................ ................................ .........................  25 
7.4.3.  Discontinuation of the Study  ................................ ................................ ............................  25 
8. TREATMENT PLAN  ................................ ................................ ................................ ................................ ... 26 
8.1. Summary of Treatment  ................................ ................................ ................................ ...................  26 
8.2. Study Design  ................................ ................................ ................................ ................................ ... 26 
8.2.1.  Induction  ................................ ................................ ................................ ...........................  26 
8.2.2.  Conso lidation  ................................ ................................ ................................ ....................  27 
8.2.3.  Maintenance  ................................ ................................ ................................ ......................  27 
8.3. Treatment with Crenolanib (AR -868,596)  ................................ ................................ ......................  28 
8.4. Dosing and Dose Modification of Crenolanib  ................................ ................................ ................  29 
8.4.1.  Dose Reductions for Non -hematologic Toxicities  ................................ ............................  29 
8.4.2.  Dose Reductions of Crenolanib for Hematologic Toxicities  ................................ ............  30 
8.5. Other Dose Hold and Dose Reduction  ................................ ................................ ............................  30 
8.6. Concomitant Therapy  ................................ ................................ ................................ ......................  30 
9. DRUG FORMULATION, AV AILABILITY, AND PREP ARATION  ................................ ........................  32 
9.1. Crenolanib  ................................ ................................ ................................ ................................ ....... 32 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 4 
Confidential  
 9.1.1.  Drug -Drug Interaction  ................................ ................................ ................................ ...... 32 
9.2. Chemotherapy  ................................ ................................ ................................ ................................ . 32 
9.2.1.  Cytarabine  ................................ ................................ ................................ .........................  32 
9.2.2.  Idarubicin  ................................ ................................ ................................ ..........................  32 
9.2.3.  Daunorubicin  ................................ ................................ ................................ ....................  32 
10. STUDY PROCEDURES  ................................ ................................ ................................ ...............................  33 
10.1.  Screening ................................ ................................ ................................ ................................ .........  33 
10.2.  Baseline … ................................ ................................ ................................ ................................ ....... [ADDRESS_661913] Characteristics  ................................ ................................ ................................ ....................  42 
13.6.  Concomitant Therapy  ................................ ................................ ................................ ......................  42 
13.7.  Response Outcome and Methodology ................................ ................................ .............................  42 
13.8.  Safety Analyses  ................................ ................................ ................................ ...............................  42 
13.9.  Criteria for End of Study  ................................ ................................ ................................ .................  43 
14. SAFETY EVALUATIONS A ND APPROPRIATENESS O F MEASUREMENTS  ................................ .... 44 
14.1.  Definitions of Adverse Events  ................................ ................................ ................................ ........  44 
14.1.1.  Adverse Event (AE)  ................................ ................................ ................................ ..........  44 
14.1.2.  Serious AE (SAE)  ................................ ................................ ................................ .............  44 
14.2.  Attribution to Study Drug  ................................ ................................ ................................ ...............  44 
14.3.  Determination of Severity  ………………………………………………………………………... 45 
14.4.  Adverse Event Reporting  ................................ ................................ ................................ ................  45 
14.5.  Serious Adverse Event Reporting  ................................ ................................ ................................ ... 46 
14.6.  Follow -up of Adverse Events ................................ ................................ ................................ ..........  47 
14.7.  Miscellaneous adverse events  ................................ ................................ ................................ .........  48 
14.8.  Deaths  …………………………………………………………………………………………… 48 
14.9.  Pregnancy  ................................ ................................ ................................ ................................ ........  49 
14.9.1.  Maternal exposure  ................................ ................................ ................................ ............  49 
14.9.2. Paternal exposure  ................................ ................................ ................................ ..............  49 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 5 
Confidential  
 14.10.  Overdose  ................................ ................................ ................................ ................................ .........  49 
15. DATA COLLECTION AND MANAGEMENT  ................................ ................................ ..........................  51 
15.1.  Data Capture System  ................................ ................................ ................................ .......................  51 
15.2.  Data Safety Monitoring Plan  ................................ ................................ ................................ ...........  51 
16. INFORMED CONSENT, ET HICAL REVIEW, AND RE GULATORY CONSIDERATI ONS  .................  52 
16.1.  Informed Consent  ................................ ................................ ................................ ............................  52 
16.2.  Document Review  ................................ ................................ ................................ ...........................  52 
16.3.  Confidentiality  ................................ ................................ ................................ ................................  52 
16.4.  Investigator Information  ................................ ................................ ................................ .................  53 
16.5.  Protocol Signatures  ................................ ................................ ................................ .........................  53 
16.6.  Final Report Signature  ................................ ................................ ................................ ....................  53 
16.7.  Publication Statement  ................................ ................................ ................................ .....................  53 
17. REFERENCES  ................................ ................................ ................................ ................................ ..............  54 
APPENDIX I. INCLUSIO N/EXCLUSION CRITERIA  CHECKLIST  ................................ ................................ ...... 55 
APPENDIX II. ECOG PE RFORMANCE STATUS CRI TERIA  ................................ ................................ ...............  58 
APPENDIX III. PATIEN T DIARIES: CRENOLANI B................................ ................................ ..............................  59 
APPENDIX IV. STUDY S CHEDULE  ................................ ................................ ................................ .......................  64 
I. Induction  ................................ ................................ ................................ ................................ .........  64 
II. Consolidation  ................................ ................................ ................................ ................................ .. 65 
III. Maintenance  ................................ ................................ ................................ ................................ .... 66 
APPENDIX V. COMMON T ERMINOLOGY CRITERIA FOR ADVERSE EVENTS; VERSION 4.03  ................  67 
APPENDIX VI. CYP3A4 DRUGS POTENTIALLY AF FECTING CRENOLANIB P HARMACOKINETICS  ...... 69 
APPENDIX VII. THE WH O CLASSIFICATION OF ACUTE MYELOID LE[LOCATION_006]EM IA[12]  ................................ .. [ADDRESS_661914] INFORMAT ION AROG PHARMACEUTI CALS  ................................ ....................  72 
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 6 
Confidential  
 Table of Tables  
Table 1 Dissociation constants of crenolanib with constitutively active FLT3 mutations  .........................  17 
Table 2 Cohort A: Cytarabine, daunorubicin induction  ................................ ................................ ..............  26 
Table 3 Cohort B: Cytarabine, idarubicin induction  ................................ ................................ ...................  [ADDRESS_661915], ALT, Alk Phos  ................................ .................  30 
Table 8 Suggested therapy for nausea and vomiting (ASCO 2011 guidelines)  ................................ ..........  31 
Table 9 Suggested therapy for diarrhea  ................................ ................................ ................................ ...... 31 
Table 10 95% confidence interval based on response rate expected in approximately [ADDRESS_661916] common resistance mutations in AML.[8]  ... [ADDRESS_661917] clearance in FLT3 mutant AML patients treated with crenolanib.  .....................  20 
Figure 6 Pharmacokinetics analyses in AML patients on 100 mg crenolanib.  ................................ ...........  21 
Figure 7 Representative PIA analysis of patient plasma samples after taking crenolanib single agent.  ..... 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 7 
Confidential  
 1. OVERVIEW OF THE TREATMENT PLAN  
 
INDUCTION  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSOLIDATION  
 
 * Daunorubicin dose:  
 90 mg/m2: Age <  60  
 60 mg/m2: Age ≥ 60 or for 
patients who are <60 and 
receiving a second cycle of 
induction (per physician’s 
discretion)  D1  D2  D3   D4   D5  D6  D7  D8  D9                                                                                                              D28 Idarubicin 12 mg/m2
 or Daunorubicin* 90/60 mg/m2 IV daily on days 1, 2, 3  Cytarabine 100 or 200 mg/m2
/day CIV days 1, 2, 3, 4, 5, 6, 7  *Crenolanib 100 mg TID PO starting approximately 24 -48 hrs after completion of Cytarabine  
D1  D2  D3   D4   D5  D6  D7                                                                                                                              D28 High dose Cytarabine IV Q12 hours on days 1, 3, 5  
Crenolanib 100 mg TID PO starting approximately 24 -48 hrs after completion of Cytarabine    Crenolanib starts approximately 24-48 hours after co mpletion of 
Cytarabine  (+7-day window) . Normal total bilirubin and ALT and 
AST ≤2.0x ULN are required within 24 hours prior to crenolanib 
commencement. Crenolanib can be delayed until th ese criteri a are  
met. (If crenolanib  will be delayed longer day 16, a discussion with PI 
[INVESTIGATOR_511753])  
 On first day of crenolanib, only one 100 mg dose given; from second 
day on, all three doses given (100 mg TID)  
 A total of tw o cycles of induction will be allowed.  
 Crenolanib should be held 72 hours prior to subsequent chemotherapy  
 Cytarabine dose: 
o Age < 60: 3000 mg /m2 (3g/m2)  
o Age ≥ 60: 1000 mg/m2 (1 g/m2) 
 On days 1,3,5 every 12 h (total of 6 doses)  
 Up to 4 cycles of consolidation allowed with 
HiDAC  
  Crenolanib starts approximately 24-48 hours after completion 
of cytarabine (+7 -day window) .  
 Normal total bilirubin  and ALT and AST ≤2.0x ULN are 
required within 24 hours prior to crenolanib 
commencement. Crenolanib can be delayed until  these 
criteri a are  met. (If crenolan ib will be delayed longer day [ADDRESS_661918] options for the patient)  
 Crenolanib should be held 72 hours prior to subsequent 
chemotherapy  

PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 8 
Confidential  
  
MAINTENANCE  
 
 A total of 12 cycles of maintenance will be allowed.  
 During maintenance, patients will take continuous crenolan ib. Cycles will be 28 days long.  
 Patients who have received HSCT and remain in remission may receive crenolanib maintenance therapy. 
Crenolanib should be restarted no sooner than [ADDRESS_661919] taken by [CONTACT_102].  
 Patient s not undergoing hematopoietic stem cell transplant who are in remission may continue on crenolanib 
after induction and/or HiDAC consolidation.  
  D1                                                                                                                                    D28 Crenolanib 100 mg TID (or last tolerated dose during induction/consolidation) PO starting on Day 1 continuously for 28 day cycles  
PROTOCOL: ARO -[ADDRESS_661920] INFORMATION  
 
Protocol Number:  ARO -006 
Version  2.0 
Version Date:  January 4, [ADDRESS_661921]:  Crenolanib Besylate  
Development Phase:  Phase II  
Sponsor:  Arog Pharmaceuticals, Inc.  
[ADDRESS_661922], Dallas TX [ZIP_CODE]  
O: (214) 593 -0500  
F: (214) 594 -0002  
Email: [EMAIL_2545]  
Medical Monitor:   John Eckardt, MD  
O: (214) 451 -4520  
M: (314) 614 -5124  
F: (214) 594 -0002  
Email: [EMAIL_9721]  
  
PROTOCOL: ARO -[ADDRESS_661923] induction and consolidation chemotherapy in patients with newly 
diagnosed AML with FLT3 activating mutations.  Acute myelogenous leukemia (AML) has a 
significant resistance to primary chemother apy with a cure rate of only 30 -40%. [1] The prognosis 
varies according to cytogenetic status. Activating mutations of FLT3 including internal tandem 
duplication (ITD) mutations within the juxtamembrane domain and single base pair mutations 
within the tyrosine kinase domain (TKD) of the receptor are the most frequent mutations described 
in AML, with a prevalence of approximately 24 -30%. [2, 3] Despi[INVESTIGATOR_511754], there is no approved target specific therapy for AML patients who harbor them.  
 
Crenolanib besylate ( AR-868,596 -26) is an orally bioavailable benzimidazole  that was designed 
to be a selective and potent inhibitor of type III receptor kinases FLT3, PDGFRα and PDGFRβ. 
Molecular binding data support that crenolanib is a type I kinase inhibitor that binds preferentially 
to the active kinase conformation of FLT3. [4] As a result of this property, crenolanib potently 
inhibits both wild type and constitutively active mutant FLT3 kinase.  In vitro studies in cell lines 
and a xenograft model have shown that  crenolanib has higher binding affinity (K d) for and potency 
(IC 50) against FLT3 kinase with internal tandem duplication (ITD) and tyrosine kinase domain 
(TKD) mutations. [2, 4, 5] A saturation mutagenesis scre en of FLT3 -ITD failed to recover any 
resistant colonies in the presence of crenolanib at a concentration significantly lower than what 
has been safely achieved in patients. [4] This high affinity of crenolanib allows it to inhibit aberrant 
FLT3 signaling at clinically achievable concentrations in AML patients.  
 
Two phase II clinical trials administered single -agent crenolanib to a total of [ADDRESS_661924] 18 evaluable who had relapsed AML patients after chemotherapy 
or allogeneic stem cell transplant (but who had not received prior FLT3 inhibitors),  crenolanib 
therapy resulted in an overall response rate of 50% (39% CR /CRi  and 11% PR).  Median overall 
survival was almost eight months (234 days).  The overall response to crenolanib monotherapy 
was 31% in 36 patients who progressed after a median of th ree prior regimens (including 
chemotherapy and FLT3 inhibitors like sorafenib, midostaurin and quizartinib). Crenolanib had a 
half-life of 7.5hrs and no crenolanib accumulation seen with repeated dosing.  Common adverse 
events (AEs) included nausea/vomitin g, transaminitis and fluid retention (majority Grade 1/2) and 
only 2 patients discontinued crenolanib due to related AEs (fatigue and nausea). No patient 
acquired a secondary FLT3 mutation at the time of relapse following crenolanib.  
 
For patients with new ly diagnosed AML, the standard chemotherapy induction regimen used in 
this study (7+3, cytarabine and anthracyclines) is considered universally as effective as any other 
regimen. [8] For this trial, crenolanib will be added to standard induction and consolidation  
chemotherapy regimens . This study will  initially  have  a safety phase with  two cohorts designated 
by [CONTACT_511787]: in c ohort A daunorubicin will be given at 90 mg/m2 for patients younger than 60 
years of age and 60 mg/m2 for patients ≥60 and in cohort B idarubicin will be given at  12 mg/m2. 
Once the safety of the combination has been established an expansion of an additional 72 pa tients 
will be initiated. During the expansion, patients will be eligible for either anthracycline regimen 
per physician ’s discretion.   
 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 11 
Confidential  
 3.2. Study Synopsis  
 
 
Title of Study:   A Study of Crenolanib and Chemotherapy in Patients with Newly Diagnosed Acute Myeloid 
Leukemia with FLT3 Activating Mutations  
 
Number of Planned Subjects: 120  
 
Approximately 48 patients will be enrolled into two cohorts  during an initial safety phase : 
Cohort A: 24 patients receiving cytarabine/ daunorubicin  followed by [CONTACT_511788] B: 24 patients receiving cytarabine/ idarubicin  followed by [CONTACT_511789]/daunorubicin and cytarabine/idarubicin has been established,  an 
expansion phase of 72 additional patients will be treated with either cytarabine/daunorubicin or with 
cytarabine/idarubicin induction chemotherapy followed by [CONTACT_511790].  
 
Length of Study:   2-3 years  
 
Primary Objectives  
 To determine the safety and t olerability of crenolanib given sequentially with chemotherapy for newly 
diagnosed AML  
 To determine the response rate to induction therapy in newly diagnosed AML subjects with FLT3 activating 
mutations when crenolanib is given sequentially with standard in duction/consolidation chemotherapy, 
including the rates of complete remission (CR), CR with incomplete blood count recovery (CRi), and partial 
response (PR).  
 
Secondary Objectives  
 To determine the overall survival (OS)  in newly diagnosed AML subjects with  FLT3 activating mutations 
when crenolanib is given sequentially with standard induction/consolidation chemotherapy  
 In those patients achieving response, assess parameters of response including: remission duration and relapse -
free survival (RFS)  
 Pharmacokinetic analysis of crenolanib when given with chemotherapy  
 
Exploratory Objectives  
To evaluate the impact of crenolanib given in combination with chemotherapy:  
 Determine steady -state serum crenolanib concentration  
 Identify and correlate specific m olecular markers with clinical outcomes  
 Determine changes in molecular markers during treatment and their correlations with clinical outcomes  
 Measure minimal residual disease (MRD) and correlate with post -remission outcomes  
 
Inclusion Criteria:  
1. Unequivocal  diagnosis of AML based on the WHO classification, excluding acute promyelocytic leukemia  
2. No prior therapy for AML, except for hydroxyurea  and/or leuk apheresis, in this setting is allowed.  
3. Subjects with AML evolving from MDS with or without  prior MDS therapy with demethylating agents  will 
be allowed in the  safety phase only .  
4. Subjects must have tested positive for FLT3 -ITD and/or other FLT3 activating mutations.   
5. Age ≥18 years  will be allowed in the safety phase ; during the expansion phase,  subjects must be ≥18 - ≤70 
years of age.  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 12 
Confidential  
 6. ECOG PS 0 – 2 
7. Adequate liver function, defined as normal total bilirubin, ALT ≤2.0x ULN, and AST ≤2.0x ULN.  
8. Adequate renal function, defined as serum creatinine ≤1.5x ULN or GFR >50 mL/min  
9. Negative pregnancy test ( serum or urine) for women of childbearing potential (WOCBP).  
 Women considered not of childbearing potential include any of the following: no menses for at least 
[ADDRESS_661925] 2 months and luteinizing hormone  
(LH) and follicular stimulating hormone (FSH) values within normal range (according to definition 
of postmenopausal for laboratory used) or bilateral oophorectomy or radiation castration and 
amenorrheic for at least [ADDRESS_661926] practice contraception. Acceptable methods of contraception are double barrier methods 
(condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, 
or injectable contraceptives, intrauterine devi ces, tubal ligations, and abstention.  
11. Male patients (except those with prior surgical contraceptive procedures) with female partners who are of 
childbearing potential: Recommendation is for male and partner to use effective contraceptive methods, such 
as latex condoms, during the study.  
12. Able and willing to provide written informed consent  
 
Exclusion Criteria:  
1. Pre-existing liver diseases (i.e., cirrhosis, chronic hepatitis B or C, nonalcoholic  steatohepatitis, and 
sclerosing cholangitis, etc.)  
2. Known a ctive CNS leukemia  
3. During the expansion phase  subjects with therapy -related AML, AML with prior history of MDS with or 
without prior HMA therapy or AML in the setting of antecedent hematologic disorder.  
4. Subject with concurrent severe and/or uncontrolled m edical conditions that may impair the participation in 
the study or the evaluation of safety and/or efficacy  
5. NYHA Class III -IV heart failure, myocardial infarction <6 months prior to study entry, and/or serious 
arrhythmia requiring anti -arrhythmic therapy  
6. Major surgical procedures within 14 days  of enrollment  (does not include line placement as needed for 
chemotherapy administration).  
7. Unwillingness or inability to comply with protocol.  
8. Concurrent use of other investigational agents.  
9. Subjects who are not el igible for standard chemotherapy  
 
Test Product, Dosage and Mode of Administration:  
Crenolanib besylate will be taken at a starting dose of [ADDRESS_661927] the date, time and amou nt (number of tablets) of crenolanib taken.  
 
Drug Information:  
Crenolanib besylate will be provided in 100 mg and /or 20 mg tablets by [CONTACT_511791], Inc.  
 
Study Design:  
Patients will initially be enrolled to the safety phase of the study. During the safety phase, patients will be enrolled to 
either cohort A: cytarabine /daunorubicin or cohort B: cytarabine /idarubicin. Each cohort will enroll independently 
and patients will  be treated with crenolanib following either cytarabine /daunorubicin or cytarabine /idarubicin.  
 
Once safety of adding crenolanib to cytarabine/daunorubicin and cytarabine/idarubicin has been established, an 
expansion phase of an additional [ADDRESS_661928] 7+3 (either cytarabine/daunorubicin or with 
cytarabine/idarubicin, per physician’s discretion) induction chemotherapy followed by [CONTACT_511792].  
 
Per physician’s discretion, patients may receive up to 2 cycles of the same induction therapy. Following induction, 
eligible patients can receive up to four cycles of consolidation with HiDAC followed by [CONTACT_511792]. Following either 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 13 
Confidential  
 induction or consolidat ion, eligible patients may receive maintenance therapy with crenolanib up to an additional 12 
cycles.  
 
Eligible  patients  should receive  allogeneic stem cell  transplant following induction and/or consolidation with HiDAC. 
Those  who have received transplant  may receive maintenance therapy with crenolanib following transplant.   
 
Planned Duration of Treatment:    
If patients receive all available therapy options, patients may stay on trial for approximately  20 months.  Information 
for survival and disease status  (until progression of disease)  on patients who have discontinued study drug for any 
reason should be obtained at least every 6 months for a maximum of 24 months or until the end of the study, whichever 
is later.  
 
Statistical Plan:   
During the initial safe ty phase, there will be two  cohort s (based on chemotherapy regimen). Each cohort will enroll 
independently. To confirm the safety of each combination (cytarabine/daunorubicin with crenolanib and 
cytarabine/idarubicin with crenolanib), a pproximately 24 patients will be enrolled onto each cohort , if early stoppi[INVESTIGATOR_511755] a are not met . Following analysis of the initial safety phase, an expansion phase of an additional 72 patients will 
be initiated to further assess safety and clinical benefit of this combinat ion.  
 
Safety analysis : 
During the initial safety phase, twelve patients will be enrolled onto each cohort and if the early stoppi[INVESTIGATOR_511756] 12 additional patients will be enrolled onto each cohort. S afety monitoring will be 
performed separately for each cohort and enrollment will be halted within a cohort if stoppi[INVESTIGATOR_511757], increase in expected non -hematologic crenolanib -related grade 4 adverse events, or a ny 
unexpected non -hematologic crenolanib -related grade 4 adverse events.  
 
Stoppi[INVESTIGATOR_511758]:  If the observed mortality rate exceeds 10 % and 20% 
at day 30 and 60, respectively, enrollment will be halted pending Protocol Safety Committee review. If an observed 
increase of expected non -hematologic crenolanib -related grade 4 adverse events exceeds 20% during the first 60 days 
of treatment further enrollment will be halted pending Protocol Safety Committee re view. If an observed increase of 
unexpected non -hematologic crenolanib -related grade 4 adverse event exceeds 15% during the first 60 days of 
treatment further enrollment will be halted pending Protocol Safety Committee review.  
 
During the expansion phase, safety monitoring will be performed for the entire per protocol patient population  (defined 
as those who receive at least one dose of study drug)  and in a separate analysis dictated by [CONTACT_511793].  
 
Response rate  analysis : 
This study will enro ll approximately 120 patients with the following confidence intervals based on projected response 
rate. A response rate of 90% will have a 95% CI of ±5%. That is to say that if we treat 120 patients and observe a 90% 
response rate, we are 95% sure that the  true response rate is between 85% to 95%.  
 
Analysis  method : 
Descriptive statistics will be used to summarize the safety and efficacy data for this study. Categorical data will be 
summarized by [CONTACT_511794]. Time – to – event endpoints will be summarized 
using the cumulative incidence and Kaplan -Meier methodology.   
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 14 
Confidential  
 4. ABBREVIATIONS AND DEFINITIONS  
Adverse Event  
(AE)  Any untoward medical occurrence in a patient or c linical 
investigation subject administered a pharmaceutical product and 
which does not necessarily have a causal relationship with this 
treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally occurring  during the use of a 
medicinal (investigational) product, whether or not related to the 
medicinal (inve stigational) product.  
Audit  A systematic and independent examination of the trial -related 
activities and d ocuments to determine whether the evaluated tr ial-
related activities were conducted, and the data were recorded, 
analyzed, and accurately reported according to the protocol, 
applicable standard operating procedures (SOPs), good clinical 
practice (GCP), and  the applic able regulatory requirement(s).  
Compliance  Adherence to all the trial -related requirements, good clinical practice 
(GCP) requirements, and the appl icable regulatory requirements.  
Complaint  A complaint is any written, electronic, or oral comm unication that 
alleges deficiencies related to t he identity, quality, purity, durability, 
reliability, safety or effectiveness, or performance of a drug or drug 
delivery system.  
Confirmation  A process used to confirm that laboratory test results meet the  quality 
requirements defined by [CONTACT_25699] g enerating the data and that 
AROG is confident that results are accurate.  Confirmation will either 
occur immediately after initial testing or will require that samples be 
held to be retested at some defined time point, depending on the steps 
requir ed to ob tain confirmed results.  
Case Report Form 
(CRF)  Sometimes referred to as clinical report form:  a printed or electronic 
form for recording study participants’ data during a clinical study, as 
required by [CONTACT_3433] e protocol.  
Consent  The act of obtaining informed  consent for participation in a clinical 
trial from patients deemed eligible or potentially eligible to participate 
in the clinical trial.  [Patients/Subjects] entered into a trial are those 
who sign the i nformed consent document directly or through their 
legally acceptable representatives.  
End of Study (trial)  The date of the last visit or last scheduled procedure shown in the 
Study Schedule for the las t active subject in the study.  
Enroll  The act of assigning a patient to a treatment.  Patients who are  enrolled 
in the trial are those who have been assigned to a treatment.  
Investig ator A person responsible for the conduct of the clinical trial at a trial site.  
If a trial is conducted by a team of individuals at a trial site, the 
investigator is the responsible leader o f the team and may be cal led 
the principal investigator.  
Insti tutional Review 
Board/Ethical Review 
Board (IRB/ERB)  A board or committee (institutional, regional, or national) composed 
of medical and nonmedical members whose responsibil ity is to verify 
that the safety, welfare, and human rights of the patients participating 
in a clinical trial are protected.  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 15 
Confidential  
 Legal Representative  An individual, judicial, or other body authorized under applicable law 
to consent on behalf of a prospective patient, to the pa tient’s 
participation in the clinical trial.  
Patient  A study participant who has the disease or condition for which the 
investigational product is  targeted.  
Screen  The act of determining if an individual meets minimum requirements 
to be come part of a p ool of potential candidates for participation in a 
clinical trial.  In this study, screening involves invasive or diagnostic 
procedures and/or tests (for example, radiology and blood draws).  
For this type of screening, informed consent for  these screening  
procedures and/or tests shall be obtained.  
Treatment -Emergent 
Adverse Event 
(TEAE)  Any untoward medical occurrence that either occurs or worsens at 
any time after treatment baseline and which does not necessarily have 
to have a causal rel ationship with this treatment (also called 
treatment -emergent sig ns and symptoms [TESS]).  
 
ALT  alanine aminotransferase  
AML  acute myeloid leukemia  
Ara-C cytarabine  
ASCO  American society of clinical oncology  
AST  aspartate aminotransferase  
BMA  bone marrow aspi[INVESTIGATOR_511759] a group b  
CBC  complete blood count  
CIV continuous intravenous therapy  
CNS  Central nervous system  
CR complete response  
CRi complete remission with incomplete blood count recovery  
CYP3A4  Cytochrome P450 3A4  
DNA  deoxyribonucleic acid  
ECOG -PS Eastern Cooperative Oncology Group performance status  
EFS Event free survival  
EKG  Electrocardiogram  
FLT3  FMS -like Tyrosine Kinase [ADDRESS_661929]  
ITD internal tandem duplication  
IV Intravenous therapy  
Kd Dissociation constan t 
KIT Stem cell growth factor receptor  
PROTOCOL: ARO -[ADDRESS_661930]  upper l imit of normal  
UPIN  Unique patient identification number  
WBC  White blood count  
WOCBP  Woman of child bearing potential  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 17 
Confidential  
 5. BACKGROUND   
5.1. Crenolanib inhibits wild-type FLT3 and its constitutively active mutations  
Crenolanib besylate (also known as AR-868,596 -26) is an orally bioavailable class III RTK 
inhibitor that potently targets FLT3. Crenolanib inhibits wild -type FLT3, and its constitutively 
active mutations at clinically achievable concentrations. [4, 5]  
 
Crenolanib has heightened binding a ffinity against the FLT3 -ITD mutation (the most frequent 
FLT3 aberration in AML) and TKD point mutations FLT3 (D835H), FLT3 (D835Y) and FLT3 
(D835V). Crenolanib binds to FLT3 -ITD and FLT3 -TKD D835H with K d values of 0.43 and 0.4 
nM, respectively. Similarly , crenolanib also binds to FLT3 -TKD D835Y with a K d of 0.18 nM. A 
saturation mutagenesis screen of FLT3 ITD showed that crenolanib is a “pan -FLT3 inhibitor” that 
has the ability to successfully suppress all resistance -conferring TKD mutants. [4] Crenolanib 
inhibitory activity has been verified in human AML cell lines. [4] 
 
Table 1 Dissociation constants of crenolanib with constitutively active FLT3 mutations  
Gene Symbol  Crenolanib K d  (nM)  
FLT3(ITD)  0.43 
FLT3(D835H)  0.4 
FLT3(D835Y)  0.18 
FLT3 (D835V)  0.[ADDRESS_661931] common resistance mutations in 
AML. [8] 
 
5.2. Crenolanib has reduced activity against KIT  
Crenolanib has been found to be approximately [ADDRESS_661932] FLT3 relative to KIT [9] and elicits c ytotoxicity in FLT3 –
mutant AML while largely sparing KIT inhibition (100 -fold offset in both viability and 
biochemical assays) with limited activity against other kinases. As a result, crenolanib may be 
associated with less myelosuppression than the availa ble type II FLT3 TKIs.   

PROTOCOL: ARO -[ADDRESS_661933] of crenolanib on nucleoside analogue uptake in AML cells was evaluated.  Cells were 
incubated for 2 h with 1.25 uM of radiolabeled cytarabine combined wit h DMSO control or in 
combination with crenolanib at 0.1 uM for 5 minutes and 2 h (Figure 2). Combining cytarabine 
with crenolanib in FLT3 wild -type OCI -AML3 cells and FLT3 -ITD MV411 cells showed that 
crenolanib does not decrease cytarabine accumulation in AML cells, despi[INVESTIGATOR_511760]. [5] 
Figure 2 Effects of crenolanib on uptake of cytar abine in AML cells.  
 
(A) 5 minute incubation; (B) 2 hour incubation.  Histogram shows mean and SD.  
 
Further combination experimentation was undertaken to give insight into the potential sequence 
of crenolanib and cytarabine administration in future clinical studies. Assays were performed to 
measure cell viability of FLT3 ITD cell lines (MOLM13 and MV4 -11) that were incubated for 4  h 
with cytarabine followed by 68 h of crenolanib (Figure 3). Results suggested synergistic activity 
with the combination [5]. 
 
Figure 3 Crenolanib and cytarabine combination synergistically inhibit FLT3 -ITD-positive 
cell viability  in vitro.  
 
(A) simultaneous 72 h drug exposure; (B) simultaneous 4 h drug exposure followed by 68 h crenolanib exposure; 
(C) (pre -AraC) 4 h AraC exposure followed by 68 h crenolanib exposure; or (D) (pre -crenolanib) 24 h crenolanib 
exposure followed by 48 h AraC exposure. [5]. 
 

PROTOCOL: ARO -[ADDRESS_661934] antileukemic synergy 
in AML cell lines with mutant FLT3 (Figure 4, unpublished data on file, [CONTACT_358738]).  
 
Figure 4 Viability of FLT3 ITD cell lines t reated with crenolanib and daunorubicin  
 
(A) Molm 13 cell line; (B) MV4 -11 cell line  
 
5.5. Clinical studies of crenolanib in AML  
 
5.5.1.  Clinical summary of crenolanib in relapsed/refractory FLT3 mutated AML  
 
Crenolanib has been studied in relapsed/refractory FLT3 mutant AML ([STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED]).  Crenolanib was administered as single -agent in 69 patients with 
relapsed/refractory FLT3 mutated AML in two clinical trials, [STUDY_ID_REMOVED]/ARO -004 and 
[STUDY_ID_REMOVED]/ARO -005. Encouraging single -agent activity, safety and P K was observed with 
crenolanib in this patient population. Amongst 18 evaluable who had relapsed AML patients after 
chemotherapy or allogeneic stem cell transplant (but who had not received prior FLT3 inhibitors), 
crenolanib therapy resulted in an overall response rate of 50% (39% CR and 11% PR).  Median 
overall survival was almost eight months (234 days).  The overall response to crenolanib 
monotherapy was 31% in 36 patients who progressed after a median of three prior regimens 
(including chemotherapy and FLT3 inhibitors like sorafenib, midostaurin and quizartinib). 
Crenolanib had a half -life of 7.5hrs and no crenolanib accumulation seen with repeated dosing.  
Common adverse events (AEs) included nausea/vomiting, transaminitis and fluid retention 
(majority Grade 1/2) and only 2 patients discontinued crenolanib due to related AEs (fatigue and 
nausea). No patient acquired a secondary FLT3 mutation at the time of relapse following 
crenolanib.  
 
 

PROTOCOL: ARO -[ADDRESS_661935] clearance in FLT3 mutant AML patients treated with crenolanib.  
 
 
In conclusion, crenolanib is a FLT3 TKI showing preliminary clinical activity in a heavily 
pretreated population with FLT3 -ITD, FLT3 -D835, and compound FLT3 -ITD/D835 mutant 
AML. Importantly, crenolanib is the first agent to demonstrate clinical activity in patients with 
FLT3 -D835 activating mutations.  
 
5.6. Tolerability of crenolanib in AML patients who had undergone prior allogeneic bone 
marrow transplant  
A retrospective analysis of those patients who, follo wing hematopoietic cell transplant (HCT), 
received monotherapy crenolanib on the relapsed/refractory AML studies (ARO -004 and ARO -
005) was performed and reported at ASH 2015. This analysis showed that crenolanib at the full 
therapeutic dose of [ADDRESS_661936] maintenance setting 
([STUDY_ID_REMOVED] / ARO -009) is on -going.  
 
5.7. Long -term Safety Data of Crenolanib  
In a Phase I pediatric gl ioma study conducted at the St. Jude Children's Research Hospi[INVESTIGATOR_307], [ADDRESS_661937] been 
studied: 100 mg  TID (28 patients)  and 200 mg/m2/day (23 patients). Crenolanib was safe and well 
tolerated in this patient population. The most common adverse events were low -grade nausea, 
vomiting, diarrhea, and transaminitis.  
 
To date, [ADDRESS_661938] been achieved. Only  2 patients had > 1000 nM 
crenolanib , but neither required  dose de-escalat ion due to adverse events . Thus, a fixed dose ITD
ITD
ITD
ITD
ITD
ITD
ITD
ITD
ITD
ITD
D835
D835
D835
ITD + D835
ITD + D835
ITD + D835
ITD + D835
ITD + D835
ITD + D835
ITD + D835
ITD + D835
ITD + D835
ITD + D835
D835
ITD
ITD
ITD
ITD
ITD + D835
ITD + D835
ITD
ITD
ITD + D835
ITD
ITD + D835
ITD + D835
ITD + D835
ITD + D835
ITD
ITD
ITD
D835
ITD + D835
ITD + D835
ITD
ITD
ITD
ITD + D835
ITD + D835
D835
ITD
ITD
ITD + D835
ITD + D835
D835
ITD
ITD
ITD + D835
ITD
ITD + D835
D835
D835
ITD + D835
ITD
ITD + D835
ITD + D835
D835 * baseline of 0
ITD + D835 * baseline of 0
D835
-100%-75%-50%-25%0%25%Maximum Change in Peripheral Blasts from BaselineITD
D835
ITD+D835
PROTOCOL: ARO -[ADDRESS_661939] shown that FLT3 phosphorylation is inhibited for 
approximately 8 hours after each dose of crenolanib (see representative PIA assay below in Figure 
7). Hence, crenol anib will be given in this protocol in a TID schedule.  
 
Figure 7 Representative PIA analysis of patient plasma samples after taking crenolanib 
single agent.  
 
The study by [INVESTIGATOR_108401] J, et al. in 16 leukemia patients showed that the major metabolites of 
idarubicin or daunorubi cin were the 13-dihydroderivative of each drug,  idarubicinol or 
daunorubicinol. The elimination half -life of idarubicinol was two times higher than that of 
daunorubicinol (80.7  h versus 37.3 h).  [6] During  7+3 induction  in this protocol , idarubicin or 
daunorubicin will be administered on days 1, 2, and 3. By [CONTACT_511795] (Day 9), 
idarubicinol level should have declined by 75% (2 half -lifes) and daunorubicinol levels will have 
dropped by 93.5% (4 half -lifes). Crenolanib will be discontinued 3 days  (9 half -lifes)  prior to 
initiation of subsequent chemotherapy.  
 
  1.010.0100.[ZIP_CODE].010000.0
0 10 20 30Crenolanib 
concentration (nM)
Time (h)

PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 22 
Confidential  
 6. STUDY OBJECTIVES  
6.1. Primary Obje ctive  
 
 To determine the safety and tolerability of crenolanib given sequentially with cytarabine and 
anthracycline chemotherapy for newly diagnosed FLT3 mutant AML.  
 To determine the response rate to induction therapy in newly diagnosed AML subjects with 
FLT3 activating mutations when crenolanib is given sequentially with standard 
induction/ consolidation chemotherapy, including the rates of complete remission (CR), CR 
with incomplete blood count recovery (CRi) and partial remission (PR).  
 
6.2. Secondary Objectives  
 
 To determine the overall survival (OS)  in newly diagnosed AML subjects with FLT3 ac tivating 
mutations when crenolanib is given sequentially with standard induction/consolidation 
chemotherapy  
 In those patients achieving response with crenolanib, assess parameters of response including 
remission duration and relapse -free survival (RFS)  
 Pharmacokinetic analysis of crenolanib when given with chemotherapy  
 
6.3. Exploratory  Objectives  
 
To evaluate the impact of crenolanib given in combination with chemotherapy:  
 Determine steady -state serum crenolanib concentration  
 Identify and correlate specific molecular markers with clinical outcomes  
 Determine changes in molecular markers during treatment and their correlations with 
clinical outcomes  
 Measure minimal residual disease (MRD) and correlate with post -remission outcomes  
  
PROTOCOL: ARO -[ADDRESS_661940] meet eligibility as defined. Clarifications of eligibility should be directed to the 
sponsor’s medical monitor.  
 
7.1. Inclusion Criteria  
 
1. Unequivocal diagnosis of AML based on WHO classification , excluding acute 
promyelocytic leukemia.  
2. No prior therapy for AML, except for hydroxyurea  and/or leukapheresis , in this setting is 
allowed.  
3. Subjects with AML evolving from MDS with or without  prior MDS therapy with 
demethylating agents  will be allowed in the safety phase only .  
4. Subjects must have tested p ositive for FLT3 -ITD and/or other FLT3 activating mutations.     
5. Age ≥18 years  will be allowed in the safety phase ; during the expansion phase,  subjects 
must be ≥18 - ≤70 years of age.  
6. ECOG PS 0 – 2 
7. Adequate liver function, defined as normal bilirubin, ALT ≤2.0x ULN, and AST ≤2.0x ULN 
measured within 24 hours prior to crenolanib commencement.   
8. Adequate renal function, defined as serum creatinine ≤1.5x ULN or GFR >50 mL/min  
9. Negative pregnancy test (serum or urine ) for women of childbearing potential (WOCBP ).  
 Women considered not of childbearing potential include any of the following:  
no menses for at least [ADDRESS_661941] 2 months and luteinizing hormon e (LH) and follicular stimulating hormone 
(FSH) values within normal range (according to definition of postmenopausal 
for laboratory used) or bilateral oophorectomy or radiation castration and 
amenorrheic for at least [ADDRESS_661942] practice contraception. Acceptable methods of contraception are double 
barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal 
jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine dev ices, tubal 
ligations, and abstention.  
11. Male patients (except those with prior surgical contraceptive procedures) with female 
partners who are of childbearing potential: Recommendation is for male and partner to use 
effective contraceptive methods, such as  latex condoms, during the study.  
12. Able and willing to provide written informed consent.  
 
7.2. Exclusion Criteria  
 
1. Pre-existing liver diseases (i.e.,  cirrhosis, chronic hepatitis B or C, nonalcoholic  
steatohepatitis, and sclerosing cholangitis , etc. ) 
2. Known a ctive CNS leukemia  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 24 
Confidential  
 3. During the expansion phase  subjects with therapy -related AML, AML with prior history 
of MDS with or without prior HMA therapy or AML in the setting of antecedent 
hematologic disorder.  
4. Subjects with concurrent severe and/or uncontrolled medical conditions that in the opi[INVESTIGATOR_511761]/or 
efficacy.  
5. NYHA Class III -IV heart failure, myocardial infarction <6 months prior to study entry 
and/or serious arrhythmia requiring anti -arrhythmic therapy  
6. Major surgical procedures within 14 days of enrollment  (does not include line placement as 
needed for chemotherapy administration ). 
7. Unwillingness or inability to compl y with protocol.  
8. Concurrent use of other investigational agents.  
9. Subjects who are not eligible for standard chemotherapy.  
 
7.3. Protocol Registration  
To register, a form [ADDRESS_661943] for the Sponsor (Appendix I). For registration, a completed Checklist is to be provided 
to the sponsor who will provide the site with a Confirmation of Enrollm ent form which will assign 
a patient study number (UPIN).  
 
7.4. Discontinuations  
 
7.4.1.  Discontinuations of  Study Drugs and Disease status/Survival Follow up of Patients  
The criteria for enrollment must be followed explicitly. If a patient who does not meet enrollmen t 
criteria is inadvertently enrolled, that patient should be immediately discontinued from the study 
drug.   
 
Study drug may be held for an extended period of time  for comorbidities including but not limited 
to infections, ICU admissions, severe graft vs h ost disease, and other comorbidities typi[INVESTIGATOR_511762], consolidation or allogeneic transplant therapi[INVESTIGATOR_317142] .  Such 
prolonged drug hold will not require the patient to be taken off study. Study drug can be restarted, 
even after prolonged drug holds, at the same dose as was last received by [CONTACT_102]. R estart of 
study drug will require a discussion with the sponsor.  
 
Study drug may be held for an extended period of time  if requested by [CONTACT_511796]. Study drug can be restarted, even after prolonged 
drug holds, at the same dose as was last received by [CONTACT_102]. Patients will be continued to be 
followed for survival  and disease status per protocol. Safety will be followed as per section 14. 
 
PROTOCOL: ARO -[ADDRESS_661944] 
of the study site  judges it necessary for medical, safety, regulatory, or other reasons consistent with 
applicable laws, regulations, and good clinical practice. Sites may also be discontinued if unable 
to accrue an adequate number of patients on the trial.  
 
7.4.3.  Discontinuation of the Study  
The study will be discontinued if the site IRB judges it necessary for medical, safety, regulatory, 
or other reasons consistent with applicable laws, regulations, and good clinical practice. The study 
could also be discontinued  at any time at the sole discretion of the sponsor, AROG 
Pharmaceuticals, Inc.  
PROTOCOL: ARO -[ADDRESS_661945] s 
with FLT3 activating mutations . Along with chemotherapy, subjects will be treated with 
crenolanib divided in three divided doses (preferably every 8 h) continuously until they fulfill one 
of the criteria for study discontinuation (see Section 7.4).  
 
Study subjects, nursing or research staff will complete documentation (i.e patient diary) during 
induction and first cycle of consolidation to record the date, time and amount (number of tablets) 
of crenolanib taken and when taken relative to food. While s tudy subjects are hospi[INVESTIGATOR_057], medical 
records, such as Medication Administration Record, may be used to enter data requested. Once 
subject is discharged from the hospi[INVESTIGATOR_307], they must submit the crenolanib administration 
documentation as required during in duction 1 (and 2 if applicable), consolidation 1 (Appendix III). 
All subjects will be assessed for efficacy and toxicity.  
 
8.2. Study Design  
This will be a Phase II multi -center study assessing the safety and clinical benefit of crenolanib 
given with standard 7 +3 induction chemotherapy in newly diagnosed in FLT3 mutated AML.  
 
Safety Phase:  Patients will receive either daunorubicin/cytarabine (Cohort A) or idarubicin/ 
cytarabine (Cohort B) per the treating hospi[INVESTIGATOR_511763].  
 
Expansion Phase:  Patients may receive e ither daunorubicin/cytarabine or idarubicin/cytarabine per 
physician’s discretion. During the expansion phase, patients may receive their standard 7+3 chemo 
of either anthracycline with cytarabine .  
 
8.2.1.  Induction  
Patients with newly diagnosed AML with FLT3 ac tivating mutations will be treated with 
crenolanib following induction with either daunorubicin/cytarabine or idarubicin/cytarabine. 
During the initial safety phase the anthracycline options will be separated into Cohort A and B. 
Induction treatment schedu les combining standard 7+3 chemotherapy with crenolanib are listed in 
Tables 2 (Cohort A) and 3 (Cohort B). During the expansion phase, the choice of anthracycline 
will not be separated into different cohorts.  
 
Crenolanib will start approximately 24 -48 ho urs after completion of cytarabine (+7 day window) . 
Adequate liver function including normal total bilirubin ALT and AST ≤2.0x ULN  are required 
within 24 hours prior to crenolanib commencement. Crenolanib can be delayed until this criterion 
is met.  (If crenolanib will be delayed longer day 16, a discussion with PI [INVESTIGATOR_511764])  
 
 
Table 2 Cohort A: Cytarabine, daunorubicin induction   
Drug  Dose  Mode  Days  
Cytarabine  100 - 200 mg/m2/day IV continuous infusion over 24 hrs  Days 1 -7 
Daunorubicin  90 mg/m2 (<60 years old)  IV bolus over 10 -15 mins  Days 1 -3 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 27 
Confidential  
 60 mg/m2 (≥60 years old  or for 
patients who are <60 and 
receiving a second cycle of 
induction (per physician’s 
discretion) ) 
 
 
Table 3 Cohort B: Cytarabine, idarubicin induction  
Drug  Dose  Mode  Days  
Cytarabine  100 - 200 mg/m2/day IV continuous infusion over 24 hrs  Days 1 -7 
Idarubicin  12 mg/m2  intravenously daily over 10 -15 mins  Days 1 -3 
 
If after induction 1, the bone marrow is hypoplastic (<10 % cellularity) on day [ADDRESS_661946]. Crenolanib treatment may be continued during this period as per the 
discretion of the treating physician.  
 
If after induction 1, the bone marrow shows residual disease without a hypocellular marrow, a 
second course of the same induction remission therapy  (or lower dose of anthracycline per Tables 
2 and 3) can be given at the decision of the treating physician. Timing and/or necessity of bone 
marrow evaluation following second induction will follow the same schedule as induction 1.  
Crenolanib must be held for [ADDRESS_661947] up to 4 consolidation courses with:  
 High dose cytarabine (HiDAC) given as 3 g/m2 (<60 years old) or 1 g/m2 (for ≥60) 
intravenously over 3 h every twelve hours on days 1, 3, 5 (total of 6 doses).  
 
Crenolanib will start approximatel y 24-48 hours after completion of cytarabine (+7 day window) . 
Adequate liver function including normal total bilirubin ALT and AST ≤2.0x ULN  are required 
within 24 hours prior to crenolanib commencement. Crenolanib can be delayed until this criterion 
is me t (If crenolanib will be delayed longer day 14, a discussion with PI [INVESTIGATOR_511764]) . 
 Dose of crenolanib will be the same as that given in induction(s).  
 Dose modification of crenolanib is allowed based on treating physician discretion 
according to Section 8.4 of this protocol.  
 
8.2.3.  Maintenance  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 28 
Confidential  
 Subjects not undergoing hematopoietic stem cell transplant who are in remission may continue on 
crenolanib after induction and /or HiDAC  consolidation. Following the last dose of cytarabine 
given for consolidation, crenolanib can be given continuously for an additional twelve cycles.   
 
Patients who undergo allogeneic transplant may receive maintenance crenolanib after transplant  if 
they fu lfill prerequisites . Subjects in remission who are scheduled for allogeneic hematopoietic 
stem cell transplant (HSCT) should discontinue crenolanib at least [ADDRESS_661948] . 
 
Prerequisites for start of maintenance are:  
 a stable dose of immunosuppressive drugs for management or prophylaxis of GVHD or  
 no escalation of therapy for GVHD within 14 days of starting study drug  
 have no more than g rade 2 persistent non -hematological toxicity related to the transplant  
 must have received crenolanib during induction for AML prior to HSCT to continue on to 
maintenance  
 
Maintenance therapy , whether following transplant or not will start at the last dose tolerated during 
induction/consolidation therapy. For example, if the patient was taking [ADDRESS_661949], maintenance therapy will resume at 80 mg TID. If well tolerat ed, 
crenolanib can be escalated to 100 mg TID. Crenolanib maintenance can be given for up to 12 
cycles and additional therapy can be provided after discussion with the sponsor.    
 
8.3. Treatment with Crenolanib (AR -868,596)  
The investigator or his/her designee is responsible for explaining the correct use of the 
investigational agent(s) to the subject or other site personnel such as inpatient staff, verifying that 
instructions are followed properly, maintaining accurate records of study drug dispensing and 
colle ction, and returning all unused and unopened medication to AROG or its designee at the end 
of the study. Study medication that has been dispensed but remains unused at the end of each cycle 
is recorded by [CONTACT_511797] o pened or returned to AROG if 
unopened with intact packaging.  
 
Subjects will be instructed to contact [CONTACT_143233] a complaint 
or problem with the study drug so that the situation can be handled.  
 
Missed Doses/Counting Cycle Days : If a subject vomits after drug ingestion, no replacement dose 
is to be taken; the subject can continue to take the remaining doses as planned. If drug is held or a 
dose is missed by [CONTACT_726] 3 hours after the scheduled time, the missed/held do se should not be 
made up. Dosing will resume with the next scheduled dose. The subject/nursing or research staff  
should enter in the diary the doses as missed  and reason for missed dose . If drug is held or missed 
for a day or more, treatment should  continu e as if uninterrupted. As pi[INVESTIGATOR_511765]; leftover drug should be returned to the 
study site by [CONTACT_511798].  
 
During induction and consolidation, one cycle is defined by [CONTACT_511799] (i.e. induction 1 = cycle 1 and may exceed 28 days) 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 29 
Confidential  
 regardless whether drug is held. During maintenance, cycles will be  28 days in maximum duration 
(28 days = 1 cycle = 1 month).  
 
“Days” of a cycle are to be counted sequentially from start of chemotherapy (not study drug) until 
start of next chemotherapy cycle. During maintenance, the start of a cycle is denoted by [CONTACT_511800]. 
The scheduled procedures/visits should comply with the study calendar regardless of amount of 
study drug administered.  
 
8.4. Dosing and Dose Modification of Crenolanib  
Subjects will be given a starting dose of 100 mg TID. Crenolanib should be held starting 72 hours 
prior to start of next induction chemotherapy cycle.   
 
Table 4 Crenolanib dose reduction schedule  
Dose level  Crenolani b dosing  
0 100 mg TID  
-1 80 mg TID  
-2 60 mg TID  
 
Reductions below 60 mg TID are not planned;  dose reductions beyond those mentioned in Table 
4 should be discussed with the sponsor and documentation justifying the specified dose should be 
recorded.  
 
8.4.1.  Dose Reductions for Non -hematologic Toxicities  
Dose reductions for non -hematologic toxicities attributed to crenolanib will be done as outlined in 
Table 5. The starting dose (dose level 0) of crenolanib will be 100 mg TID. A maximum of two 
(2) dose reductions are allowed in a single subject for toxicities related to crenolanib. Please refer 
to Table [ADDRESS_661950] 
and/or Alkaline Phosphatase.  
 
Table 5 Crenolanib dose reduction for non -hematologic toxicities related to crenolanib  
Toxicity (CTCAE v4.03)  Dose Modification  
Grade 1 or 2  No dose modification  
Grade 3 or 4 (except nausea, vomiting 
or diarrhea)  Hold drug until toxicity resolves to grade 1 or less. Restart drug 
at next lower dose level (see Table 4) 
Grade 3 or 4 nausea, vomiting or 
diarrhea  despi[INVESTIGATOR_511766] 
72 hours of onset  Hold d rug until toxicity resolves to grade 1 or less. Restart drug 
at next lower dose level (see Table 4) 
 
Table [ADDRESS_661951] toxicity (CTCAE Grade)  Recommended Dose Modifications  
Grade 1 bilirubin elevation (ULN - 1.[ADDRESS_661952])  Continue crenolanib at current dose  
Grade ≥2 or bilirubin elevation (>1.[ADDRESS_661953])  Stop crenolanib. Restart drug at next lower dose 
level ( -1) (Table 4) once bilirubin returns to normal.  
Following re -challenge:   
Grade ≥2 or bilirubin elevation (>1.[ADDRESS_661954])  Stop crenolanib. Restart drug at next lower dose 
level ( -2) once bilirubin returns to normal.  
 
PROTOCOL: ARO -[ADDRESS_661955] toxicity (CTCAE Grade)  Recommended Dose Modifications  
Grade [ADDRESS_661956] elevation (ULN - 3.[ADDRESS_661957]) 
and/or Alk phos (ULN - 2.[ADDRESS_661958])  Continue crenolanib at current dose  
Grade ≥[ADDRESS_661959] elevation (>3.[ADDRESS_661960]) and/or 
Alk phos (>2.[ADDRESS_661961])  Stop crenolanib. Restart drug at next lower dose 
level ( -1) (Table 4) once ALT, AST and/or Alk 
Phos returns to ≤ grade 1  
Following re -challenge:   
Grade ≥[ADDRESS_661962] elevation (>3.[ADDRESS_661963]) and/or 
Alk phos (>2.[ADDRESS_661964])  Stop crenolanib. Restart drug at next lower dose 
level ( -2) once ALT, AST and/or Alk Phos returns 
to ≤ grade [ADDRESS_661965] be approved by [CONTACT_170196] . 
 
8.5. Other Dose Hold and Dose Reduction  
Dose hold due to  toxicity unrelated to crenolanib or other medical intervention s may be allowed 
on a cas e by [CONTACT_413]. Investigator should discuss with sponsor prior to any dose hold for reasons 
other than toxicity related to crenolanib. All dose hold should be captured in CRFs.    
 
8.6. Concomi tant Therapy  
All supportive therapy for optimal medical care will be given during the study period at the 
discretion of the attending physician(s) within the parameters of the protocol and documented with 
source documents on CRF s as concomitant medication.  
 
Supportive measures including blood and platelet transfusions, a ntimicrobials including 
prophylaxis, etc. are permitted. The use of growth factors is allowed per institutional practice 
guidelines or the preference of the attending physician.  
 
Chemotherapy not specified on this protocol, investigational cytotoxic agent s, radiation, or 
biologic therapy is prohibited while the subject  is on study with the following exceptions during 
induction:  
1. Leukapheresis is allowed within the first 10 days of induction of the study only. Please 
notify the study’s medical monitor if le ukapheresis is required beyond this specification.  
2. Hydroxyurea (up to a maximum of 5 g/d) for a maximum of [ADDRESS_661966] 28 
days on trial may be administered during induction.  
3. Leukapheresis and hydroxyurea may be administered together according to the guidelines 
above.  
 
The parameters of exposure to leukapheresis and/or hydroxyurea apply as of cycle 1, day [ADDRESS_661967] induction.  Patients who commenced hydroxyurea and/or leukapheresis prior to enrollment 
are allowed to participate.    
 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 31 
Confidential  
 Except for t he chemotherapy or hydroxyurea specified in this protocol no other anticancer therapy 
including immunotherapy, hormonal cancer therapy, or experimental medications will be 
permitted while patients are participating in this study. Any disease progression re quiring other 
forms of specific antitumor therapy will be cause for discontinuation of study therapy.  
 
In clinical trials, crenolanib caused nausea and vomiting in >60% patients (2 -5% Grade 3/4 events, 
data unpublished, on file at AROG) and diarrhea in 50%  of patients (4% Grade 3/4 events, data 
unpublished, on file at AROG). Therefore, the recommendation is made that standard anti -emetic 
premedication is given (see Table 8). Prophylaxis can be discontinued if subject tolerates 
crenolanib without significant  nausea and vomiting. Infectious work -up for diarrhea will be left to 
the discretion of the Investigator, using institutional guidelines. Treatment with antidiarrheal drugs 
is recommended once the onset of the earliest signs of diarrhea is present (see Tab le 9).  
 
It has not been established whether enzyme inducing drugs alter the dosing of crenolanib in 
patients. However, CYP3A4 is required for the metabolism of crenolanib in experiments done with 
hepatic microsomes. Therapeutic agents which are potential hepatic enzyme CYP3A4 inducing or 
inhibiting drugs should be used with caution in patient participation on the study, see Appendix 
VI. 
Table 8 Suggested therapy for nausea and vomiting (ASCO 2011 guidelines)   
Escalation of therapy  Drug or class  Directions  
[ADDRESS_661968]  30 minutes prior to crenolanib 
administration  1 Metoclopramide  
2 Dexamethasone  
  
Table 9 Suggested therapy for diarrhea  
Escalation of therapy  Drug or class  Directions  
0 Loperamide  As per investigators discretion, not 
to exceed maximum recommended 
dose 1 Lomotil  
 
These are suggested guidelines; subjects should be treated according to investigator/treating 
physician discretion.  
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 32 
Confidential  
 9. DRUG FORMULATION, AVAILABILITY, AND PREPARATION  
9.1. Crenolanib  
Crenolanib besylate is supplied as 100 mg and/or [ADDRESS_661969] party. 
Clinical trial materials will be labeled ac cording to regulatory requirements.  
 
Crenolanib besylate tablets should be refrigerated at a temperature between 2 C and 8C (35.6F 
and 46.4F). Standard household refrigeration is considered adequate for drug storage. Crenolanib 
should be stored in the v ials provided by [CONTACT_128913]. Used 
bottles , unused tablets and bottles and drug diaries should be returned to the study site.  
 
9.1.1.  Drug -Drug Interaction  
It has not been established whether enzyme inducing drugs alter the  dosing of crenolanib in 
patients. However, CYP3A4 is required for the metabolism of crenolanib in experiments done with 
hepatic microsomes. Therapeutic agents which are potential hepatic enzyme CYP3A4 inducing or 
inhibiting drugs should be used with cauti on in patient participation on the study, see Appendix 
VI. 
 
9.2. Chemotherapy  
Only qualified personnel familiar with procedures that minimize undue exposure to themselves or 
the environment should undertake the preparation, handling, and safe disposal of chemot herapeutic 
agents in a self -contained, protective environment. Institutional protocols for preparation, dosing 
and discarding chemotherapeutic agents should be followed.  
 
9.2.1.  Cytarabine  
Please see package insert for additional information.  
 
9.2.2.  Idarubicin  
Please see package insert for additional information.  
 
9.2.3.  Daunorubicin  
Please see package insert for additional information.  
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 33 
Confidential  
 10. STUDY PROCEDURES  
After providing informed consent, screening procedures may start with the patients assigned 
unique patient identi fication number (UPIN). The UPIN will consist of a n eight -digit number 
where the first t hree digits will mark the protocol ID ( 006). The second two numbers will mark the 
site and will be determined by [CONTACT_456]. And the third will mark the patient sequen tially. (ie. 
[ADDRESS_661970] patient enrolled from site 1 onto protocol ARO -006). The Sponsor 
should be provided with the complete “Enrollment Checklist” indicating the request to enroll the 
patient to the trial. After review, the sponsor will p rovide the site a “Confirmation of Enrollment” 
signifying enrollment of the patient to the trial and formal verification of the study unique patient 
identifier number (UPIN).   
 
10.1. Screening  
The following assessments will be performed after completion of the informed consent and within 
[ADDRESS_661971] of care can be used for screening purposes as long as done within the window required .  
 
1. Medical history and physical exam (includes documentation of current medications , prior 
relevant surgeries or treatments,  allergies  and prior or existing relevant medical conditions ) 
2. Height, weight, vital signs  
3. Demographics  
4. ECOG Performance Status (Appendix II)  
5. Serum or urine pregnancy tes t for women of child bearing capacity  (within 7 days of 
enrollment ) 
6. Chemistry panel including creatinine, total bilirubin, ALT, and AST (within 7 days of 
enrollment)  
7. CBC with differential (within 7 days of enrollment)  
8. Bone marrow aspi[INVESTIGATOR_12752]  (within 21 days of enrollment).  
9. Evaluation of FLT3 -D835, FLT3 -ITD and other mutational status ( within  21 days of 
enrollment ).   
 
10.2. Baseline  
Baseline (first day of crenolanib) should be performed as follows:  
1. Chemistry panel including total bilirubin, ALT and  AST should be collected within 24 
hours of initiation of crenolanib. Eligibility criteria ( Section 7.1.7 ) should be reconfirmed 
at this time point. If patient does not have normal total bilirubin and ALT/AST ≤ 2x ULN 
at this time point, crenolanib can be delayed until these criteria  are met ( section 1 overview 
of treatment plan ). 
2. Baseline EKG should be collected after completion of chemotherapy (within 24 hours  of 
start of crenolanib ) and a second EKG should be performed 2 hour (± 30 minutes) post first 
dose of crenolanib  
3. Active concomitant medications within 24 hours of initiation of  crenolanib  
4. CBC with differential collected after completion of chemotherapy and prior to initiation of 
crenolanib  
5. PS, Physical exam with vitals after completion of chemotherapy and prior to initiation of 
crenolanib  
6. Active toxicities or medical conditions after completion of chemotherapy and prior to 
initiation of crenolanib  
PROTOCOL: ARO -[ADDRESS_661972] correlative studies at all time points for all patients; however, missing collection in 
one or more of these time points will not be considered a protocol deviation/ violation.  
 
10.3. Evaluation during treatment   
Counting Cycle Duration:  During induction and consolidation, one cycle is defined by [CONTACT_511801] (i.e. induction 1 = cycle 1 and 
may exceed 28 days ). During maintenance, cycles will be 28 days in maximum duration (28 days 
= 1 cycle).  
 
It is assumed subjects will be in the hospi[INVESTIGATOR_511767] (induction and consolidation). 
Required study patient evaluations should be performed as an inpatient or o utpatient including:  
 
1. Physical examination (with ECOG PS, vital signs and weight) and medical history update 
(including concomitant medications), and documentation of adverse events:  
a. During induction(s) : Routinely per institutional standard of car e , at response 
assessment visit (Day 14 -28), and at count recovery (or day 42) whichever occurs 
first.  
b. During consolidation(s)  Day [ADDRESS_661973] of care    
c. During maintenance : Day [ADDRESS_661974] schedule but no less frequent 
than every 2 months (±1 month).  
2. EKG measurements to be obtained during induction and consolidation therapy.  
a. EKG to be obtained 2 hour (± 30 minutes) post  first dose of crenolanib in consolidation 
1. 
3. CBC with platelet count an d differential (differential may be omitted if WBC is <0.5 
x109/L) must be obtained at least   
a. During induction(s): Routinely per  institutional standard of care (at least once 
weekly) , at response assessment visit (Day 14 -28), and at count recovery (or day 
42) whichever occurs first.  
b. During consolidation(s) : Routinely per institutional standard of care  (at least once 
weekly) . 
c. During maintenance : Day [ADDRESS_661975] 
a. During induction(s): Routinely per institutional standard of care (at least once 
weekly) , at response assessment visit (Day 14 -28), and at count recovery (or day 
42) whichever occurs  first. 
b. During consolidation(s) : Routinely per institutional standard of care (at least once 
weekly).  
c. During maintenance : Day 1 of each cycle   
5. Bone marrow aspi[INVESTIGATOR_511768]:  
a. During induction (s): Between days  14-28, bone marrow is obtained per standard 
of care to evaluate for remission/response to therapy  and a t time of count recovery 
or Day 42  (whichever occurs first)   
b. Bone marrow sampling during consolidations should occur per institutional 
standard of care.    
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 35 
Confidential  
 c. During maintenance : should occur per institutional standard of care  (reference 
study calendar appendix IV) .   
6. Blood and marrow samples for translational research including pharmacokinetic analysis 
will be obtained as defined in Section [ADDRESS_661976] correlative studies at all time points for all patients; however, missing collection in 
one or more of these time points will not be considered a protocol deviati on/violation.  
7. Serum or urine pregnancy test for women of child bearing capacity should be done every 
six months while on study.  
 
10.4. At time of progression or completion of study  
1. Medical history and physical exam (includes documentation of current medications)  
2. Weight, vita l signs, ECOG Performance Status (Appendix II)  
3. Adverse event documentation  
4. CBC  with platelet count, differential (differential may be omitted if WBC is <0.5 x109/L) 
5. Chemistry panel including creatinine, total bilirubin, ALT, and AST  
6.  bone marrow and whole blood samples  
7. Evaluation of FLT3 -D835, FLT3 -ITD and other mutational status when available  
 
* Every effort should be made to collect optional procedures at all time points for all patients; 
however, missing collection in one or more of these time points will not be considered a protocol 
deviation/violation.  
Procedures that are to be performed at the planned subject visits will be granted an exemption if 
the subject is hospi[INVESTIGATOR_511769], or otherwise medically unstable as determined by 
[CONTACT_511802]. In the latter case, the investigator is responsible 
to ensure that the planned protocol procedures are performed at a local hospi[INVESTIGATOR_511770]. Appropriate documentation and source documents shall be ob tained and information 
recorded onto study CRFs.  
 
 
 
  
PROTOCOL: ARO -[ADDRESS_661977] AROG (Appendix VIII) to 
request lab kits in anticipation of each patient enrolled on the study.  
 
Correlative samples to be collected  include but are not limited to:  
1. Serum for p harmacokinetic (PK) analysis (selected sites only)  
2. Bone marrow aspi[INVESTIGATOR_337] (BMA ) samples  
3. Bone marrow smears  
4. Whole blood sample  
 
Sampling Schedule for PK (selected sites only)  
Serial blood samples for PK will be drawn for correlative research. See lab manual for  forms. 
During crenolanib treatment, PK will be drawn for the following time points:  
 
Day [ADDRESS_661978]-dose 2 hours (± 15 minutes)    
c. post-dose 4 hours (± 30 minutes)   
d. post-dose 8 hours (± 2 h)  
e. post-dose 24 hours (± 6 h) prior to first dose of the day  
 
Day [ADDRESS_661979]-dose 4 hours (±30 minutes)  
For patients who proceed to consolidation with HiDAC:  
Day [ADDRESS_661980]-dose 4 hours (±30 minutes)  
c. post-dose 8 hours (± 2 h)   
 
Please make sure that the time and dose of last four crenolanib administrations are captured 
on PK forms.  
 
Sampling Schedule for Bone Marrow Aspi[INVESTIGATOR_511771], an additional aspi[INVESTIGATOR_19860] 2.5 mL should be drawn 
for research purposes and placed in a heparinized cell preparation tube. See lab manual  for required 
form.  
 
Scheduled bone marrow time points per protocol:  
a. During induction(s): day 14 -28 and at time of count recovery (or Day 42 ), 
whichever occurs first  
b. During consolidations: as per the institutional standard of care  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 37 
Confidential  
 c. Maintenance: as per the institutional standard of care . 
d. When patient is determined to have progressive disease by [CONTACT_30780] (loss of CR/CRi).  
 
Sampling Schedule for Whole Blood Collection  
Samples of 5 -10 mL of whole blood are drawn and placed in heparinized cell preparation tubes for 
other correlative science research studies. See lab manual  for required form. Samples should be 
drawn at the following two time points:  
 
a. Pre-administration of first dose of anthracycline in induction 1  (when applicable) , 
b. Upon progression  
 
Sample Processing Instructions  
See lab manual for processing, storage and shipment of samples.  
 
Sampling Schedule for Other Correlative Studies  
Additional samples for correlative research may be collected at any time while the patient is on 
study, at the discretion of the investigator or as requested by [CONTACT_456]. These may include assays 
for resistance studies for cases in which responses are noted but not durable.  Samples can be stored 
and collected and send at interim intervals. AROG may request the investigator obtain additional 
samples from the patients; the total blood drawn for these studies will be less than 200 ml in any 
month.  
 
Samples will be stored at AROG or its designated facility for future correlative science research 
studies.  
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 38 
Confidential  
 12.  RESPONSE DEFINITIONS  
12.1. Response Criteria  
Response criteria will be adapted from the International Working Group for AML. [9] Responders 
are newly diagnosed patients receiving study drug who obtain a CR, CRi, or PR, with or without 
cytogenetic response, hematologic improvements, and morphologic leukemia -free state. Briefly, 
criteria are as foll ows:  
 
1. Complete remission (CR):  
a. Peripheral blood counts:  
i. No circulating blasts  
ii. Neutrophil count ≥1.0 x109/L  
iii. Platelet count ≥100 x109/L 
b. Bone marrow aspi[INVESTIGATOR_12752]:  
i. < 5% blasts  
ii. No Auer rods  
iii. No extramedullary leukemia  
 
2. Complete remission with incomplete  blood count recovery (CRi):  
a. Peripheral blood counts:  
i. No circulating blasts  
ii. Neutrophil count <1.0 x109/L, or  
iii. Platelet count <100 x109/L 
b. Bone marrow aspi[INVESTIGATOR_12752]:  
i. < 5% blasts  
ii. No Auer rods  
iii. No extramedullary leukemia  
 
3. Partial remission :  
a. All CR criteria except:  
b. 50 % reduction in bone marrow blast but within  5-25% or  
c. Marrow blasts < 5% with persistent Auer rods  
 
4. Morphologic leukemia -free state :  
a. Bone marrow: <5% myeloblasts   
 
5. Hematologic Improvement (HI):  
Hematologic response must be described  by [CONTACT_511803].  
a. Blast response (B)  
i. At least  a 50% reduction in blast percentage in peripheral blood (if > 5%) 
or bone marrow  
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 39 
Confidential  
 13.  STATISTICAL CONSIDERATIONS  
13.1. Statistical and analytical plans  
The statistical analysis of this study will be the responsibility of AROG Pharmaceuticals or its 
designees. The clinical research physician/scientist and statistician will jointly be responsible for 
the appropriate conduct of an internal review process for the final study report and any s tudy-
related material to be authorized for publication by [CONTACT_307820]. A statistical analysis 
plan (SAP) will be prepared as a separate document that details the planned analyses and 
presentation of the study results.  
 
13.1.1.  General considerations  
The statistical analyses will be performed by [CONTACT_511804], with the cohorts combined. 
Descriptive statistics will be used to summarize the safety and efficacy data for this study. 
Continuous data will be summarized by [CONTACT_190378], mean,  standard deviation, median, 
minimum, and maximum value. Categorical data will be summarized by [CONTACT_511805]. Time -to- event endpoints will be summarized using the 
cumulative incidence and Kaplan -Meier methodology,  as appropriate.  
 
13.1.2.  Determination of sample size  
A total of approximately 120  patients will be enrolled. The study consists of a safety phase and an 
expansion phase. The safety phase has two arms in which patients will  receive cytarabine in 
combination with daunorubicin  (Cohort A) or with idarubicin (Cohort B) during standard 7+[ADDRESS_661981] induction 
chemotherapy with crenolanib.  
 
Historically, patients with newly diagnosed FLT3+ve AML achieve a 66%  - 69% response rate 
with induction chemotherapy only.  (Mandelli et al. J Clin Oncol. 2009;27(32):5397 -403) In recent 
years, Midostaurin (a FLT3 TKI) has shown an improvement of response rate to 74 -76% with the 
combination of Midostaurin to standard induct ion chemotherapy. (Schlenk et al. Blood 2016; 
128(22): 449) This study will enroll approximately 120  patients with the following  confidence 
intervals based on projected response rate. A response rate of 90% will have a 95% CI of ±5%. 
That is to say that if  we treat 120 patients and observe a 90% response rate, we are 95% sure that 
the true response rate is between 85% to 9 5%.  
 
 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 40 
Confidential  
 Table 10 95% confidence interval based on response rate expected in approximately 120 
patients  
Response Ra te 95% CI  True response rate interval   
90%  ±5%  85%-95% 
85%  ±6%  84%-96% 
80%  ±7%  83%-97% 
75%  ±8%  82%-98% 
 
13.2. Safety monitoring  during the initial safety phase  
Adverse events, as defined in Section 14.1, will be monitored during the treatment and post-
treatment follow up periods. Adverse events will be monitored on a continuous basis by [CONTACT_103].  
 
The Protocol Safety Committee will review safety data from this trial on a periodic basis. The 
committee also will monitor the safety outcomes listed below for purposes of determining if 
enrollment in one or both cohorts should continue or be halted. Within each cohort, up to [ADDRESS_661982] 6 patients, p atients will be enrolled in a sequential manner 
such that no mo re than 3 patients are within 30 days of starting induction 1 therapy. Enrollment 
will be halted within a cohort if an apparent increase is observed in the occurrence of one or more 
of the following outcomes:  
 Early mortality due to any cause  
 Expected, non -hematologic, crenolanib -related toxicity (CTCAE Grade 4)  
 Unexpected, non -hematologic, crenolanib -related toxicity (CTCAE Grade 4)  
 
The criteria used to determine if enrollment will be halted are described in sections  13.2.1 , 13.2.2  
and 13.3.3 .  
 
13.2.1.  Excessive  early mortality  
Early stoppi[INVESTIGATOR_511772]. Early 
mortality is defined for this study as death due to any cause within 30 and 60 days of the initiation 
of study treatment. In the VALOR tri al, all-cause  mortality rates of 7.9% and 19.7% were reported, 
respectively, for patients with relapsed/refractory AML who received cytarabine and placebo as 
induction therapy. [14]  The 30 -day mortality rate of 7.9% from the VALOR trial is similar to the 
28-day mortality rate of 10.3% that was reported from a retrospective analysis of more than 3000 
patients with newly diagnosed AML, the majority of whom were treated wit h cytarabine -based 
regimens as induction therapy. [11] 
 
Based on the above considerations, enrollment in a cohort will be halted if the observed 30 - and 
60-day early mortality rate exceeds 10% and 20%, respectively, as fo llows: if [ADDRESS_661983] been met.  
 
For the second group of 6 patients within a cohort, if 2 or more o f the patients enrolled within a 
cohort die prior to Day 30, then enrollment of additional patients will be halted pending review by 
[CONTACT_511806]. Similarly, if 3 or more of the patients enrolled within a cohort die 
PROTOCOL: ARO -[ADDRESS_661984] frequently reported, irrespective 
of severity:  
 hepatic dysfunction  
 nausea, vomiting, and diarrhea  
 ascites, edema, and effusions  
  
The majority of these events were CTCAE severity grade 1 -3, with grade 4 representing less than 
5% of total cases report ed. It’s anticipated that these or similar adverse events also occur with 
relatively higher frequency for AML induction regimens that include cytarabine, idarubicin, or 
daunorubicin. Nonetheless, for purposes of monitoring enrollment in this study, the adv erse events 
listed above represent the expected non -hematologic crenolanib -related toxicities. I f the observed 
rate of expected, non -hematologic, crenolanib -related toxicity with CTCAE severity grade 4 
exceeds 20% during the first 60 days of treatment, the n enrollment will be halted as follows:  
 
If [ADDRESS_661985] been met. Upon enrollment of the 6 additional patients within a 
cohort, if 3 or more of the patients enrolled within a cohort experience such an event prior to Day 
60, then enrollment of additional patients will be halted pending review by [CONTACT_511807]. If these and the other early stoppi[INVESTIGATOR_377156], then 12 additional patients 
will be enrolled to the cohort.  
 
13.2.3.  Exce ssive unexpected crenolanib -related toxicity  
Early stoppi[INVESTIGATOR_511773] -related toxicity will be applied in the 
safety phase of the study. An unexpected  crenolanib -related toxicity is defined as any non -
hematologic, adverse event considered related to crenolanib ( exclusive of those listed in Section 
13.2.2). If the observed rate of unexpected, non -hematologic, crenolanib -related toxicity with 
CTCAE severity grade 4 exceeds 15% during the first 60 days of treatment  then e nrollment within 
a cohort will be halted as follows:  
 
If [ADDRESS_661986] been met. Upon enrollment of the 6 additional patients within a 
cohort, if 2 or more of the patients enrolled within a cohort experience such an event prior to Day 
60, then enrollment of additional patients will be halted pending revi ew by [CONTACT_511807]. If these and the other early stoppi[INVESTIGATOR_377156], then 12 additional patients 
will be enrolled to complete the cohort.  
PROTOCOL: ARO -[ADDRESS_661987] induction 
chemotherapy with crenolanib.  
 
13.3.1.  Safety monitoring during the expansion phase  
During the expansion phase, safety monitoring will be performed for the entire per protocol patient 
population (defined as those who receive at least one dose of study drug) and in a separate analysis 
dictated by [CONTACT_511793].  
 
13.3.2.  Response Rate Evaluation  
At the expansion phase, the primary end -point is overall response rate. Patients must have received 
at least one dose of study drug and have at least one bone marrow disease assessment to be included 
in the complete response rate.   
 
13.4. Subject Disposition  
A summary of patient disposition will be provided for each cohort and will include the following:  
 Number of patients enrolled  
 Number of patients who participate in each study phase (induction, consolidation, 
maintenance)  
 Reasons for discontinuation from stud y treatment and follow -up 
 Summary of major protocol violations  
 
13.5. Subject Characteristics  
Patient characteristics will be reported for each cohort, and will include a summary of the 
following:  
 Demographics  
 Baseline disease characteristics  
 Pre-existing condit ions 
Other characteristics will be summarized as deemed appropriate.  
 
13.6. Concomitant Therapy  
Concomitant medication will be reported overall as well as summarized in a frequency table using 
the terms recorded on the CRF. If warranted, an attempt may be made to determine how 
concomitant medications are related to observed study outcomes.  
 
13.7. Response Outcome and Methodology  
Response criteria will be adapted from the International Working Group for AML, as stated in 
section 12.1. 
 
13.8. Safety Analy ses 
All subjects will  be evaluable for safety. Adverse events that occur after a subject is entered (signs 
informed consent), but before the patient receives study drug, will not be recorded on the CRF 
unless the investigator believes that the events may have been caused by a protocol procedure. 
Safety analyses will include summaries of the incidence of adverse events by [CONTACT_511808]: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 43 
Confidential  
 grade (version 4.03; NCI 2010) that occur during the study treatment period or within [ADDRESS_661988] dose of study treatment or until altern ate therapy is started, regardless of causality or 
relatedness to study drug. The safety -related outcomes that will be summarized include:  
 Adverse events,  
 TEAEs,  
 SAEs,  
 Deaths,  
 Discontinuations due to adverse events,  
 Extent of exposure to study drug treatment,  
 Hospi[INVESTIGATOR_602],  
 Use of key concomitant medications.  
 
Analyses for data with discrete dates (for example, death date and start/stop dates of concomitant 
medications) will be performed through [ADDRESS_661989] be followed until the event has resolved or stabilized.  
 
13.9. Criteria for End of Study  
This study will be considered complete following the data cut -off date for the fina l analysis.  
Documentation of the data cut -off will be included in the master study file.  After the final analysis, 
if subjects are continuing to benefit from study treatment, they will be allowed to continue 
receiving study treatment for up to one year as  part of planned maintenance. Patient is considered 
“off therapy” when study drug stops for any reason and crenolanib therapy is not continued.  
Patient is considered “off study” after completion of the [ADDRESS_661990].  
 
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 44 
Confidential  
 14. SAFETY EVALUATIONS AND APPROPRIATENESS OF  MEASUREMENTS  
14.1. Definitions of Adverse Events  
 
14.1.1.  Adverse Event (AE)  
Any harm or untoward medical occurrence in a research participant administered a medical 
product, medical treatment or procedure even if it does not necessarily have a causal relationship 
with the product, treatment, or procedure. An adverse event can be any unfavorable and unintended 
sign (including an abnormal laboratory finding, for  example), symptom, or disease temporally 
associated with the use of a medical product, medical treatment, or procedure whether or not 
considered to be related. All adverse events regardless of grade must be recorded, graded, and 
reported to the Sponsor.  
 
14.1.2.  Serious AE (SAE)  
An adverse event that results in any of the following outcomes:  
• Death  
• Life-threatening adverse event (real risk of dying)  
• Hospi[INVESTIGATOR_063]  
• Prolongation of hospi[INVESTIGATOR_059]  
• Persistent or significant disability/incapacity/or change in psych osocial status  
• Congenital anomaly  
• Requirement of intervention to prevent permanent impairment or damage  
 
14.2. Attribution to Study Drug  
For reporting purposes, attribution is the assessment of the likelihood that an adverse event is 
caused by [CONTACT_144614]. The attribution is assigned by [CONTACT_1961] [INVESTIGATOR_144571], th e medical history of the subject, and past 
experience with the research agent/intervention. This is recorded using one of the following four 
categories:  
 Related  
 Possibly Related  
 Not Related  
 Unknown  
 
Related means that the adverse event was most certainly caused by [CONTACT_32015].  
 
Possibly related means that there is reasonable possibility that the adverse events may have been 
caused by [CONTACT_3459].  
Not related means that the adverse event was due to an underlying disease, disorder, or condition 
of the subject, or may have been caused by [CONTACT_511809], disorder, or condition of the subject.  
 
Unknown means that it is unclear whether the adverse even t was related to procedures involved in 
the research, either because more information is needed, and will be provided in follow -up, or 
because there is no way to make a determination.  
 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 45 
Confidential  
 An AE is “related or possibly related to the study drug or research procedures”  if in the opi[INVESTIGATOR_104271], it was more likely than not caused by [CONTACT_28821]. AEs that 
are solely caused by [CONTACT_113363], disorder or condition of the subject or by [CONTACT_511810], disorder or condition of the 
subject are not “related or possibly related”. If there is any question whether or not an AE is related 
or possibly related, the AE should be reported.  
 
14.3. Determination of Severity  
The severity of AEs will be assessed according to the Common Terminology Criteria for Adverse 
Events (CTCAE), Version 4.03. If the AE is not defined in the CTCAE, the investigator will 
determine the severity based on the following definitions from the CTCAE:  
 Grade 1 (Mild): Asymptomatic or mild symptoms, clinical or diagnostic observations only 
with no intervention indicated  
 Grade 2 (Moderate): Minimal, local or noninvasive intervention indicated, limiting 
instrumental ADL  
 Grade 3 (Severe): Medically significan t but not immediately life -threatening, causing 
hospi[INVESTIGATOR_318], disabling and limiting self -care AL  
 Grade 4 (Life -Threatening): Urgent intervention indicated  
 Grade 5 (Death)  
 
14.4. Adverse Event Reporting  
AROG has standards fo r reporting AEs that are to be followed regardless of applicable regulatory 
requirements that may be less stringent . Lack of drug effect is not an AE in clinical trials, because 
the purpose of the clinical trial is to establish drug effect.  
 
Adverse Events  (AEs) will be evaluated according to CTCAE version 4.[ADDRESS_661991].  After the Informed Consent Document (ICD) is signed, study site personnel will 
record the occurrence and nature of each patient’s p re-existing conditions, including  clinically 
significant signs and symptoms of the disease. During the study, site personnel will record any 
change in the pre -existing condition(s) and the occurrence and nature of any new adverse events.   
 
All AEs related to protocol procedures are report ed to AROG or designee. All AEs occurring after 
the patient receives the first dose of study drug must be reported to AROG or its designee via CRF. 
Investigators will be instructed to report to AROG or its designee their assessment of the potential 
related ness of each AE to protocol procedure, studied disease state, study drug, and/or drug 
delivery system via CRF.  
 
For all AEs, the investigator should specify:  
1. Seriousness:  Seriousness of an AE is defined by [CONTACT_511811] 10.1. A 
severe AE should not always be considered as serious.  
2. Date of onset and its duration (start and end dates) : The investigator should follow up the 
outcome of any AEs until they re turn to normal or consolidation of the subject's condition. 
All adverse events still evolving at the end of the study are to be followed up by [CONTACT_511812].  
3. Severity:  (using NCI CTCAE v.4.03),  
PROTOCOL: ARO -[ADDRESS_661992] to study drug:  (no action taken; study drug  dosage 
adjusted/temporarily interrupted; study drug  permanently discontinued due to this adverse 
event; hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059]), corrective treatment/therapy given, 
additional investig ations performed  
5. Outcome:  Resolved/Recovered, recovering/resolving, not recovered/resolved, 
recovered/resolved with sequelae, unknown  
6. Relatedness : If an AE is related or not related to study drug  
 
Follow-up of unresolved adverse  events 
Any AEs that  are unreso lved at the subject’s  last visit in the study are to be followed up by [CONTACT_511813]. The sponsor retains the right to request addition al 
information for any subjec t with ongoing AE(s) at  the end  of the study, if judged necessary. 
 
CASE OF ROUTINE LABORATORY MEASUREMENTS  
A value outside the normal or reference range in a routine safety assessment, such as clinical 
laboratory may be considered as an AE. However, laboratory, as well as vital signs abnormalities, 
are to be recorded into the eCRF as AEs only if they are consid ered medically relevant  by [CONTACT_1275]: i.e. symptomatic, requiring corrective treatment, leading to IMP 
discontinuation/dose modification (reduction and/or delay), and/or fulfilling a seriousness 
criterion.  Deterio ration  of a laboratory value that is unequivocally due to disease  progression  
should  not be  repor ted as an AE. If the findings contribute to a clinical diagnosis (such as hepatitis 
in case of increased liver enzymes) this diagnosis should be recorded as an adverse event.  
 
14.5. Serious Adverse Event Reporting  
Serious adverse event collection begins after the patient has signed informed consent and has 
received a tablet or more of study drug. If a patient experiences an SAE after signing informed 
consent, bu t prior to receiving study drug, the event will NOT be collected unless the investigator 
feels the event may have been caused by a protocol procedure.  
 
In case of a SAE, the investigator, within [ADDRESS_661993] 
notify the sponsor (Arog Pharmaceuticals by  e-mail: SAE@ arogpharma .com or Fax: 214 -594-
0002) and transmit the following information (within a signed SAE report form):  
 Subject identification code, demographics and vitals  
 Description of event with onset and duration (with CTCAE event term & severity)  
 Dates, dose and frequency of study drug administered  
 Assessment of the seriousness and causality of the event with the study drug using the 
causality criteria (EVCTM): related versus not related  
 Study drug status (dose interrupted or discontinued)  
 Date of  death (if applicable)  
 Concomitant therapy and interventions  
 Pertinent laboratory data/diagnostic tests  
 Pertinent medical history including underlying diagnosis  
PROTOCOL: ARO -[ADDRESS_661994]’s 
death. This may mean that follow -up will be extended beyond the subject’s withdrawal from the 
trial. The investigator must provide follow -up information (outcome, more precise medical details, 
results of investigations, copy of discharge summary, etc …) within [ADDRESS_661995] 
period. The evaluation of expectedness is based on knowledge of the adverse reaction on the 
reference document: the current refer ence document is the latest version of the Investigator’s 
Brochure of crenolanib.  
 
The sponsor will also inform the IRB of any SAE with the potential to modify the benefit/risk r atio 
of the present study. The sponsor will be responsible for reporting of New Safety Issues and Annual 
Safety Reports to IRBs.  
 
The following events are not  to be considered as a SAE:  
 Any event requiring short consultation in a hospi[INVESTIGATOR_307]  
 An external treatment in a hospi[INVESTIGATOR_511774]  
 Any event clearly related to disease progression   
o Disease progression can be considered as a worsening of a patient’s condition 
attributable to the disease for which the investigational product is being studied. It  
may be an increase in the severity of the disease under study and/or increases in the 
symptoms of the disease. The development of new, or progression of existing 
metastasis to the primary cancer under study should be considered as disease 
progression and not an AE or SAE. Events that are unequivocally due to disease 
progression should not be reported as AEs or SAEs during the study.  
 Hospi[INVESTIGATOR_059] (1 night or more) or hospi[INVESTIGATOR_511775]:  
o Planned hospi[INVESTIGATOR_059] f or routine intervention  
o Hospi[INVESTIGATOR_511776]  
o Hospi[INVESTIGATOR_511777] a modification of the subject’s health  
o Hospi[INVESTIGATOR_511778] (for example: hospi[INVESTIGATOR_511779])  
o Hospi[INVESTIGATOR_511780] a subject’s health worsening and not related to the 
study objectives (for example: plastic surgery)  
 
14.6. Follow -up of Adverse Events  
All adverse events will be  followed up according to Good Clinical Practice.  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 48 
Confidential  
  
During Treatment:   During study, site personnel will track any change in the condition(s) and 
the occurrence and nature of any AEs and record the highest grade of the adverse event per cycle 
on the CRF. CT CAE grading will be assigned before each visit for any adverse event s experienced 
during the previous visit period.  
 
Preparation for transplant : Once patient enters conditioning prior to transplant, crenolanib will 
be held (72 hours prior to start of conditioning). Patients will not be followed for safety once 
conditioning starts. If patient receives maintenance crenolanib following transplant, saf ety will be 
assessed once patient restarts crenolanib (per protocol).  
 
Discontinuation due to relapse:  
Patients who have discontinued therapy due to relapse will be followed for safety for [ADDRESS_661996].  
 
Discontinuation due to toxicity:  
Patients who have discontinued therapy due to toxicities attributable to study drug will be followed 
for safety for [ADDRESS_661997].   
 
Long -Term Follow -Up Period :  Only new and ongoing serious adverse events ( SAEs)  thought 
to be related to study treatment or protocol procedures should be documented on the CRF and 
immediately reported to AROG or i ts designee via the designated transmission method. If drug -
related toxicity is present beyond [ADDRESS_661998] 
for 30  days or until the toxicity resolves.  
 
14.7. Miscellaneous adverse events  
New safety issues : Any new safety data that could lead to re -evaluate the ratio between the benefits 
and the risks of the research, or that could be sufficiently important to consider modifications of 
the research documents, the research management or, if need be, the drug uti lization.  
 
New cancers: The development  of a new cancer should  be regarded as an  AE and will general ly 
meet  at least one of the serious criteria. New  cancers are those that are not the primary reason for 
the administ ration of the study treatment and have been identified after the subject ’s inclusion  in 
this study. They do not  include  metastases  of the original cancer. 
 
14.8. Deaths  
All deaths  that occur  during the study should  be repor ted as follows:  
• Death,  which  is unequiv ocally due to disease  progression,  should  be communicated to  
the study monitor  at the next monitor ing visit and should  be document ed in the CRF  
module,  but should  not be reported  as a SAE  during  the study 
• Where death  is not clearly due to disease progression of the  disease  under study the AE 
causi ng the death should  be reported  to the study monitor  as an  SAE  within  24 hours of 
becoming aware of the event. The  report should  contain  a comment  regarding the co-
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 49 
Confidential  
 involvement  of progression of disea se, if appropriate,  and should  assign a single 
primary cause of death  together  with any contributo ry causes 
• Deaths  with an unknown  cause  should  always be reported  as a SAE (within 24 hours of 
becoming aware of the event) but  every effort should  be made  to establ ish a cause  of 
death.  A post-mortem  may be helpful in the assessment  of the  cause of death,  and if 
performed,  a copy of the  post-mortem results  (with  translation  of important  parts  into 
English) should  be reported  in an expedited fashion  to the sponsor  within  the usual 
timeframes 
 
14.9. Pregnancy  
Nothing  is known about the effects of crenolanib on reproductive function. Women of reproductive 
potential and fertile men will be informed as to the potential risk of procreation while participating 
in this trial . 
If the investigator has been informed that a fem ale subject is pregnant during the study period:  
1. The investigational product should be immediately discontinued and the planned safety 
assessments should be performed  
2. The investigator must immediately notify the study monitor, complete the Pregnancy 
Report  Form, and send it to Arog Pharmaceuticals by e -mail: SAE@ arogpharma .com or 
Fax: 214 -594-0002.  
3. Follow -up of the pregnancy will be mandatory until the outcome has been determined.  
Nota bene : In order to follow the pregnancy of the wife of a subject include d in the study, consent 
or agreement of the subject’s wife should appear in the medical file of the subject.   
 
14.9.1.  Maternal exposure  
Pregnancy itself is not regarded as an adverse event. Congenital  abnormalities/birth  defects  and 
spontaneous miscarri ages should  be reported  and handled  as SAEs. Elective  abortions  without 
complications  should  not be handled  as AEs.  The outcome  of a pregnancy should  be followed up 
and documented  even  if the patient was withdr awn from  the study. 
 
If a pregnancy occurs during exposure  to investig ational  product  or in  the [ADDRESS_661999] inform the 
sponsor  immediately, or no la ter than 24  hours  of when he or she beco mes aware of it. The  same 
timelines apply when outcome information  is available. 
 
14.9.2.  Paternal exposure  
Pregnancy of a patient’s  partner  is not conside red to be an adverse event. Howev er, any conception  
occurring from the date of dosing until [ADDRESS_662000] shown an apparent crenolanib half -life of approximately 8 hours. It is anticipated that 
PROTOCOL: ARO -[ADDRESS_662001] 
inform the sponsor immediately, or no later than 24 hours  of when he/she becomes aware of it.  
 
Such overdoses should be recorded as fo llows:  
 An overdose with associated AEs/SAEs is recorded as the AE diagnosis/symptoms on the 
relevant AE/SAE modules in the eCRF.  
 An overdose with no associated symptoms should be documented on the eCRF module for 
dosing of study drug.  
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 51 
Confidential  
 15.  DATA COLLECTION A ND MANAGEMENT  
To ensure accurate, complete, and reliable data, AROG or its representatives will do the following:  
 Provide instructional material to the study site, as appropriate.  
 Sponsor a start -up training session to instruct the investigators and study coordinators. 
This session will give instruction on the protocol, the completion of the CRFs, and 
study procedures.  
 Conduct periodic teleconferences (approximately twice a month ) with each study site 
to discuss current patients on trial, available pharmaco dynamics/pharmacokinetic 
data, regulatory issues and other updates as applicable.  
 Make periodic visits to the study site.  
 Be available for consultation and stay in contact [CONTACT_86203], 
telephone, and/or fax.  
 Review and evaluate CR F data and use audits to detect errors in data collection.  
 Conduct a quality review of the database.  
 
In addition, AROG or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study site. The study may be audited by [CONTACT_511814], and/or regulatory agencies at any time. Investigators will be given notice before 
an audit occurs.  
 
To ensure the safety of participants in the study, and to ensure accurate, complete, and reliable 
data,  the investigator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study. If requested, the investigator 
will provide the sponsor, applicable regulatory agencies, a nd applicable ethical review boards 
(ERBs) with direct access to original source documents.  
 
15.1. Data Capture System  
An electronic data capture system will be used in this trial. Case report form (CRF) data will be 
encoded and stored in a clinical trial databa se. Any data that will serve as the source document 
will be identified and documented in the site’s study file.  
 
15.2. Data Safety Monitoring Pl an 
AROG and Investigator, or his/her designee, will have periodic teleconferences  (approximately 
twice a month)  with each study site to discuss current patients on trial, available 
pharmacodynamics/pharmacokinetic data, regulatory issues and other updates as applicable.  
   
AROG will have Data Safety Monitoring meetings at least every six months or for every 6 patients 
enrolled per cohort. At these meetings, compi[INVESTIGATOR_511781].  
  
PROTOCOL: ARO -[ADDRESS_662002] 
throughout the study and sharing in a timely manner any new information that may be relevant to 
the patient’s willingne ss to continue his or her participation in the trial. Patients must also be 
informed that they may withdraw from the study at any time and for any reason without 
jeopardizing their future treatment. In accordance with federal regulations (21 CFR 50), all p atients 
enrolled in the study must sign the IRB -approved consent form.  
 
The informed consent document (ICD) will be used to explain the potential risks and benefits of 
study participation to the patient in simple terms before the patient is entered into th e study, and 
to document that the patient is satisfied with his or her understanding of the risks and benefits of 
participating in the study and desires to participate in the study.  
 
The investigator is responsible for ensuring that informed consent is giv en by [CONTACT_229204]. This includes obtaining the appropriate signatures and dates on the ICD prior to the 
performance of any protocol procedures and prior to the administration of study drug.  
 
16.2. Document Review  
In accordance with feder al regulations (21 CFR 312.66), an Institutional Review Board (IRB) that 
complies with regulations in [ADDRESS_662003] be compliant with the International Conference on Harmonization (ICH) 
guideline on good clinical pra ctice (GCP). Informed consent obtained under special circumstances 
may occur only if allowed by [CONTACT_511815] a 
written process approved by [CONTACT_128937].  
 
Any member of the IRB who is directly affiliated with this stud y as an investigator or as site 
personnel must abstain from the IRB’s vote on the approval of the protocol.  
As well as documentation required by [CONTACT_3452]’s IRB(s), the following will be provided:   
 Current Study Protocol  
 The current Investigator’s Brochure or package labeling and updates during the 
course of the study  
 Informed consent document  
 
16.3. Confidentiality  
Patient medical information obtained for the purposes of this study is confidential, and disclosure 
to third parties, other than those note d above, is prohibited. Upon the patient’s request and written 
permission, medical information may be given to his/her personal physician or other appropriate 
medical personnel responsible for the patient’s welfare. Data generated for this study must be 
PROTOCOL: ARO -[ADDRESS_662004] to representatives of the national or local health authorities, and 
the associated IRB/IEC. Release of research results or data that reveal patient names or other 
identifiers, such as photographs, audio or videotapes, must  be carried out in accordance with 
Department of Health and Human Services Final Standards for Privacy of Individual Health 
Information, [ADDRESS_662005] be obtained from the patient and 
IRB/IEC prior to the release of such inform ation. Identifiable patient data may not be used for 
purposes of promoting any drugs used in this trial.  
 
16.4. Investigator Information  
Physicians with a specialty in oncology will participate as investigators in this clinical trial.  
 
16.5. Protocol Signatures  
After reading the protocol, each principal investigator [INVESTIGATOR_141689] a copy of the signed page to an AROG representative.  
 
16.6. Final Report Signature  
[CONTACT_511171], which may be the Principal In vestigator, will 
sign the final clinical study report for this study, indicating agreement that, to the best of his or her 
knowledge, the report accurately describes the conduct and results of the study.  
 
The sponsor’s responsible medical officer will sig n the final clinical study report for this study, 
confirming that, to the best of his or her knowledge, the report accurately describes the conduct 
and results of the study.  The final clinical study report will be written by [CONTACT_456].  
 
16.7. Publication State ment  
The results of this clinical trial may be used for public dissemination in the form of papers, 
abstracts, posters, or other informational materials to be presented at scientific meetings, or 
published in professional journals, or as a part of an academic thesis by [CONTACT_2413].  
 
Identifiable patient data may not be used for any of these presentations, manuscripts, or reports 
unless directed by [CONTACT_2371].  
 
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 54 
Confidential  
 17.  REFERENCES  
1. Rowe, J.M. and M.S. Tallman, How I treat acute myeloid leukemia. Blood, 2010. 116(17): 
p. [ADDRESS_662006] resistance -
conferring point mutants. Blood, 2014. 123(1): p. 94 -100. 
3. Schlenk, R.F., et al., Mutations and treatment outcom e in cytogenetically normal acute 
myeloid leukemia. N Engl J Med, 2008. 358(18): p. 1909 -18. 
4. Smith, C.C., et al., Crenolanib is a selective type I pan -FLT3 inhibitor. Proceedings of the 
National Academy of Sciences of the [LOCATION_002] of America, 2014.  111(14): p. [ADDRESS_662007] models of drug -resistant FLT3 -ITD-
positive acute myeloid leukemia. Blood, 2013. 122(22): p. 3607 -15. 
6.        Robert J, et al., Comparative pharmacokinetic study of idarubicin and daunorubicin in 
leukemia patients. Hematol Oncol. 1992.10(2): p.111 -6.7. Collins, R., et al., Clinical 
activity of Crenolanib in patients with D835 mutant FLT3 -positive relapsed/refractory 
acute myeloid leukemia (AML). J Clin Oncol, 2014. 32:5s(suppl; abstr 7027).  
8. Lichtman, M.A., A historical perspective on the development of the cytarabine (7days) and 
daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th 
anniversary of 7+3. Blood cells, molecules & diseases, 2013. 50(2 ): p. 119 -30. 
9. Cheson, B.D., et al., Revised recommendations of the International Working Group for 
Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting 
Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of clinical oncology 
: official journal of the American Society of Clinical Oncology, 2003. 21(24): p. 4642 -9. 
10. Kottaridis, P.D., et al., The presence of a FLT3 internal tandem duplication in patients with 
acute myeloid leukemia (AML) adds important progno stic information to cytogenetic risk 
group and response to the first cycle of chemotherapy: analysis of 854 patients from the 
[LOCATION_008] Medical Research Council AML 10 and 12 trials. Blood, 2001. 98(6): p. 
1752 -9. 
11. Walter, R.B., et al., Prediction of early death after induction therapy for newly diagnosed 
acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment 
assignment. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology, 2011. 29(33): p. 4417 -23. 
12.  Mandelli et al. J Clin Oncol. 2009;27(32):5397 -403 
13.  Schlenk et al. Blood 2016; 128(22): 449  
 
 
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 55 
Confidential  
 Appendix I. Inclusion/Exclusion Criteria Checklist  
All subjects enrolled must meet eligibility criteria based on the inclusion/exclusion criteria 
detailed in the application and approved by [CONTACT_1201].  
 
I. Study Information  
 
Protocol Title:  A Study  of Crenolanib and Chemotherapy with Cytarabine and 
Anthracyclines in  Patients with Newly Diagnosed Acute Myeloid 
Leukemia  
with FLT3 Activating Mutations  
Protocol Number:  ARO -[ADDRESS_662008] Information:  
 
Subject Name/ID:   
Gender:    x Male     x  Female  
 
III. Inclusion/Exclusion Criteria  
 
Inclusion Criteria  
(From IRB approved protocol)  Yes No N/A Supporting 
Documentation*  
1. Unequivocal diagnosis of AML based on the 
WHO classification, excluding acute 
promyelocytic leukemia.      
2. No prior therapy for AML, except for 
hydroxyurea and/or leukapheresis , in this 
setting is allowed.      
3. Subjects with AML evolving from MDS with or 
without  prior MDS therapy with demethylating 
agents  will be allowed in the safety phase only .     
4. Subjects must have tested positive for FLT3 -ITD 
and/or other FLT3 activating mutations.      
5. Age ≥18 years  will be allowed in the safety 
phase ; during the expansion phase,  subjects 
must be ≥18 - ≤70 years of age.      
6. ECOG PS 0 – 2     
7. Adequate liver function, defined as normal 
bilirubin, ALT ≤2.0x ULN, and AST ≤2.0x ULN  
measured within 24 hours prior to the induction 
chemotherapy.      
8. Adequate renal function, defined as serum 
creatinine ≤1.5x ULN or GFR >50 mL/min      
PROTOCOL: ARO -[ADDRESS_662009] (serum or urine) for 
women of childbearing potential (WOCBP).  
 Women considered not of 
childbearing potential include any of 
the following: no menses for at least  
[ADDRESS_662010] 2 months 
and luteinizing hormone (LH) and 
follicular stimulating hormone 
(FSH) values within normal range 
(according to definition of 
postmenopausal for laboratory used) 
or bilateral oophorecto my or 
radiation castration and amenorrheic 
for at least [ADDRESS_662011] practice contraception. 
Acceptable methods of contraception are double 
barrier methods (condoms with spermicidal jelly 
or foam and diaphragm with spermicidal jelly or 
foam), oral, depo provera, or injectable 
contraceptives, intrauterine devices, tubal 
ligations, and abstention.      
11. Male patients (except those with prior surgical 
contraceptive procedures) with female partners 
who are of childbe aring potential: 
Recommendation is for male and partner to use 
effective contraceptive methods, such as latex 
condoms, during the study.      
12. Able and willing to provide written informed 
consent.      
Exclusion Criteria  
(From IRB approved protocol)  Yes No N/A Supporting 
Documentation*  
1. Pre-existing liver diseases (i.e., cirrhosis, chronic 
hepatitis  B or C, nonalcoholic steatohepatitis, 
and sclerosing cholangitis , etc.)       
2. Known a ctive CNS leukemia      
3. During the expansion phase  subjects with 
therapy -related AML, AML with prior history of 
MDS with or without prior HMA therapy or 
AML in the setting of antecedent hematologic 
disorder.      
4. Subject with concurrent severe and/or 
uncontrolled medical conditions that in the 
opi[INVESTIGATOR_511782]/or efficacy.      
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 57 
Confidential  
 5. NYHA Class III -IV heart failure, myocardial 
infarction  <6 months prior to study entry and/or 
serious arrhythmia requiring anti -arrhythmic 
therapy      
6. Major surgical procedures within 14 days of 
enrollment  (Does not include line placement as 
needed for chemotherapy administration )     
7. Unwillingness or inability to comply with 
protocol.      
8. Concurrent use of other investigational agents.      
9. Subjects who are not eligible for standard 
chemotherapy.      
 
*All subject files must include supporting documentation to confirm subject eligibility. The 
method of confirmation can include, but is not limited to, laboratory test results, radiology test 
results, subject self -report, and medical record review.   
 
IV. S tatement of Eligibility  
 
This subject is [x eligible  / x ineligible ] for participation in the study.  
 
Signature:   [CONTACT_1782]:   
 
Printed Name:   
 
  
[INVESTIGATOR_11208]: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 58 
Confidential  
 Appendix II. ECOG Performance Status Criteria  
Performance Status Criteria  
ECOG (Zubrod)  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity, but ambulatory, and able to carry out work 
of a light or sedentary nature, e.g., light housework, office work  
2 Ambulatory and capable of self-care, but unable to carry out any work activities, up 
and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair for more than 50% of 
waking hours  
4 Completely disabled; cannot carry on any self care; total ly confined to bed or chair  
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 59 
Confidential  
 Appendix III. Patient Diaries: Crenolanib  
Cycle No:_________ This section to be completed by [CONTACT_511816]: Crenolanib  
Besylate ( AR-868,596 -26) 
Protocol ID: ARO -006 
Prescribed Dose:_________ mg TID, Dosing:______100 mg tablets_________20 mg tablets    
 
SUBJECT ID                                                                       SUBJECT INITIAL  
            
 
Day Date  
___/___/___  
m     d      y  Time 
Taken  
(HR-
MIN  
AM/PM  Number of 
Tablets 
Taken (100 
mg Tablet)  Number of 
Tablets 
Taken (20 
mg Tablet)  If Dose Skipped 
Please Provide the 
Reason/s  With Food  If Yes, please 
provide 
Description of 
Meal  Any Side 
Effects (Please 
Complete 
Adverse Events 
Form in Detail)  
1  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
2  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
3  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
4  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
5  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
6  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
7  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 60 
Confidential  
 Cycle No:_________ This section to be completed by [CONTACT_511816]: Crenolanib  
Besylate ( AR-868,596 -26) 
Protocol ID: ARO -006 
Prescribed Dose:_________ mg TID, Dosing:______100 mg tablets_________20 mg tablets    
 
SUBJECT ID                                                                      SUBJECT INITIAL  
            
 
Day Date  
___/___/___  
m     d      y  Time 
Taken  
(HR-
MIN  
AM/PM  Number of 
Tablets 
Taken (100 
mg Tablet)  Number of 
Tablets 
Taken (20 
mg Tablet)  If Dose Skipped 
Please Provide the 
Reason/s  With Food  If Yes, please 
provide 
Description of 
Meal  Any Side 
Effects (Please 
Complete 
Adverse Events 
Form in Detail)  
8  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
9  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
10  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
11  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
12  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
13  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
14  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 
 
 
 
 
 
 
 
 
 
 
 
 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 61 
Confidential  
 Cycle No:_________ This section to be completed by [CONTACT_511816]: Crenolanib  
Besylate ( AR-868,596 -26) 
Protocol ID: ARO -006 
Prescribed Dose:_________ mg TID, Dosing:______100 mg tablets_________20 mg tablets    
 
SUBJECT ID                                                                        SUBJECT INITIAL  
            
 
Day Date  
___/___/___  
m     d      y  Time 
Taken  
(HR-
MIN  
AM/PM  Number of 
Tablets 
Taken (100 
mg Tablet)  Number of 
Tablets 
Taken (20 
mg Tablet)  If Dose Skipped 
Please Provide the 
Reason/s  With Food  If Yes, please 
provide 
Description of 
Meal  Any Side 
Effects (Please 
Complete 
Adverse Events 
Form in Detail)  
15  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
16  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
17  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
18  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
19  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
20  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
21  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 
 
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 62 
Confidential  
 Cycle No:_________ This section to be completed by [CONTACT_511816]: Crenolanib  
Besylate ( AR-868,596 -26) 
Protocol ID: ARO -006 
Prescribed Dose:_________ mg TID, Dosing:______100 mg tablets_________20 mg tablets    
 
SUBJECT ID                                                                        SUBJECT INITIAL  
            
 
Day Date  
___/___/___  
m     d      y  Time 
Taken  
(HR-
MIN  
AM/PM  Number of 
Tablets 
Taken (100 
mg Tablet)  Number of 
Tablets 
Taken (20 
mg Tablet)  If Dose Skipped 
Please Provide the 
Reason/s  With Food  If Yes, please 
provide 
Description of 
Meal  Any Side 
Effects (Please 
Complete 
Adverse Events 
Form in Detail)  
22  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
23  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
24  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
25  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
26  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
27  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
28  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 
 
 
 
 
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 63 
Confidential  
 Cycle No:_________ This section to be completed by [CONTACT_511816]: Crenolanib  
Besylate ( AR-868,596 -26) 
Protocol ID: ARO -006 
Prescribed Dose:_________ mgTID, Dosing:______100 mg tablets_________20 mg tablets    
 
SUBJECT ID                                                                       SUBJECT INITIAL  
            
 
Day Date  
___/___/___  
m     d      y  Time 
Taken  
(HR-
MIN  
AM/PM  Number of 
Tablets 
Taken (100 
mg Tablet)  Number of 
Tablets 
Taken (20 
mg Tablet)  If Dose Skipped 
Please Provide the 
Reason/s  With Food  If Yes, please 
provide 
Description of 
Meal  Any Side 
Effects (Please 
Complete 
Adverse Events 
Form in Detail)  
  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
  ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 ___/___  
AM/PM     ___/___  
YES/NO    
 
 
PROTOCOL: ARO -[ADDRESS_662012] day of 
crenolanib  Weekly 
following 
start of 
crenolanib  Day 14 -28 
(response 
assessment visit)  Day 42  ± (3 days)  
or at count 
recovery+ 
(whichever is first)  Weekly until end 
of cycle  (if cylce 
is extended past 
42 days ) 
Demographics  X      
Relevant medical history, current medical conditions 
including AML -specific history  X      
Evaluation of FLT3 and other mutational status  X    X  
Prior/Concomitant medications  and significant non -drug 
therapi[INVESTIGATOR_014]  X X Per SOC  X X Per SOC  
Physical examination  with ECOG P S  X X Per SOC  X X Per SOC  
EKG b  X**       
Vitals, Weight, and Height  (only at screening) X X Per SOC  X X Per SOC  
Assessment of adverse events, toxicities   X Per SOC  X X Per SOC  
Hematology (CBC with differential) X* X X d X X X d 
Serum Chemistries (CMP with bilirubin, ALT/AST and 
creatinine)  X* X X d X X X d 
Urine or serum pregnancy test  X  Every 6 months while patient is on study  
Blood collections for PK and correlative sciences  c  X** (drawn per Section 11)  
Bone marrow biopsy and aspi[INVESTIGATOR_20325] e X*   X e X  
 
Key:  
+ count recovery is defined as  : ANC ≥1000 and platelets ≥100,000  
a Screening assessments should be performed within 28 days of enrollment with the following exceptions: CBC, CMP and pregnancy test (when applicable) should be performed within 7 days of enrol lment, 
bone marrow biopsy and aspi[INVESTIGATOR_511783]3 and other mutational status  should be performed within 21 days of enrollment  
* If screening assessments were performed while patient was receiving induction chemotherapy, the following assessmen ts performed prior to starting induction, if done per standard of care, may be 
requested by [CONTACT_456]: CBC with differential, CMP with bilirubin, ALT/AST, and bone marrow biopsy and aspi[INVESTIGATOR_1516]  
b EKG  is to be performed pre -dose crenolanib (baseline on the  first day of crenolanib) as well as 2 hours (± 30 minutes) post first dose of crenolanib during Induction 1  
c Peripheral and whole blood samples for translation research (including PK analysis) should be collected as defined in Section  11.  
** EKG, Periph eral blood for PK analysis and Whole blood sample will only be collected during Induction [ADDRESS_662013] FLT3 testing and mutational status if available  
Per SOC:  Physician visits (with ECOG PS, vitals, weight, concomitant medication assessment and adverse events assessments) should be performed as per SOC while patients are receiving  crenolanib 
during induction. At a minimum adverse events and concomitant medications should be reported to the sponsor (per EDC) m onthly.   
PROTOCOL: ARO -[ADDRESS_662014] day of 
crenolanib  Weekly following start of crenolanib  
Prior/Concomitant medications  and significant non -drug therapi[INVESTIGATOR_014]  X X Per SOC  
Physical examination  with ECOG P S  X X Per SOC  
EKG a  X*   
Vitals and  Weight X X Per SOC  
Assessment of adverse events, toxicities  X X Per SOC  
Hematology (CBC with differential) c X X X 
Serum Chemistries (CMP with bilirubin, ALT/AST and creatinine) c X X+ X 
Urine or serum pregnancy test  Every 6 months while patient is on study  
Blood collections for PK and correlative sciences  b  X*  
Bone marrow biopsy and aspi[INVESTIGATOR_20325] e d Per SOC  
 
Key:  
a EKG is to be performed 2 hours (± 30 minutes) post first dose of crenolanib during Consolidation 1  
b Blood samples for translation research (including PK analysis) should be collected as defined in Section 11.  
* EKG and blood for PK will only be collecte d during Consolidation [ADDRESS_662015] additional labs done per S OC be captured  
+ Prior to initiation of crenolanib (within [ADDRESS_662016] dose) following HiDAC consolidation, bilirubin, ALT and AST must meet eligibility criteria as depi[INVESTIGATOR_511784] [ADDRESS_662017] FLT3 testing and mutational status if available  
Per SOC: Physician visits (with ECOG PS, vitals, weight, concomitant medication assessment and adverse events assessments) sh ould be performed as per SOC while patients are receiving crenolanib 
during induction. At a minimum adverse events and concomitant medications should be reported to the sponsor (per EDC) monthly.  
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 66  
Confidential  
 III. Maintenance  
 
Assessment  Maintenance 1 -12 At time of progression  or 
completion of study  
Day within cycle  Day 1  (± 14 days)   
Prior/Concomitant medications, 
significant non -drug therapi[INVESTIGATOR_014]   X a X 
Physical examination with ECOG PS   X a X 
Vitals and weight   X a X 
Assessment of adverse events, 
toxicities   X a X 
Hematology (CBC with differential) X X 
Serum Chemistries (CMP with 
bilirubin, ALT/AST and creatinine)  X X 
Urine or serum Pregnancy test  Every 6 months while patient 
is on study   
Whole blood sample  b  X 
Bone marrow biopsy and aspi[INVESTIGATOR_337]  c Per SOC  X 
 
Key:  
a Day [ADDRESS_662018] schedule but no less frequent than every 2 months (±1 month).  
b Whole blood samples for translation research should be collected as defined in Section 11.  
c Bone marrow biopsy and aspi[INVESTIGATOR_511785]3 testi ng and mutational status if available  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 67 
Confidential  
 Appendix V. Common Terminology Criteria for Adverse Events; Version 4.03  
Cardiac Disorders  
 Grade  
Adverse Event  1 2 3 4 5 
Anorexia  
Definition : A disorder 
characterized by [CONTACT_511817].  Loss of appetite in eating 
habits  Oral intake altered 
without significan t weight 
loss or malnutrition; oral 
nutritional supplements 
indicated  Associated with 
significant weight loss or 
malnutrition (e.g. 
inadequate oral caloric 
and/or fluid); tube feeding 
or TPN indicated  Life-threatening 
consequences; urgent 
intervention indi cated  Death  
Diarrhea  
Definition : A disorder 
characterized by [CONTACT_511818] <4 stools per 
day over baseline; mild 
increase in ostomy output 
compared to baseline  Increase of 4 -6 stools per 
day over baseline; 
moderate increase in 
ostomy output compared 
to baseline  Increase of ≥7 stools per 
day over baseline; 
incontinence; 
hospi[INVESTIGATOR_374]; 
severe increase in ostomy 
output compared to 
baseline; limiting self care 
ADL  Life-threatening 
consequences; urgent 
intervention indicated  Death 
Fatigue  
Definition : A disorder 
characterized by a state of 
generalized weakness with a 
pronounced inability to 
summon sufficient energy to  
accomplish daily activities.  Fatigue releved by [CONTACT_511819], limiting instrumental 
ADL  
 Fatigue not releved by 
[CONTACT_9075], limiting self care 
ADL  _ _ 
Nausea  
Definition : A disorder 
characterized  by [CONTACT_511820]/or the urge to 
vomit.  Loss of appetite without 
altering in eating ha bits Oral intake decrease 
without significant weight 
loss, dehydration or 
mainutrition  Inadequate oral caloric or 
fluid intake; tube feeding, 
TPN, or hospi[INVESTIGATOR_373]  _ _ 
Vomiting  
Definition : A disorder 
characterized by [CONTACT_511821].  1-2 epi[INVESTIGATOR_1841]  (separated 
by 5 minutes) in 24 hrs  3-5 epi[INVESTIGATOR_1841] (separated by 
5 minutes) in 24 hrs  ≥6 epi[INVESTIGATOR_1841] (separated by 
5 minutes) in 24 hrs; tube 
feeding, TPN or 
hospi[INVESTIGATOR_80157]-threatening 
consequences; urgent 
intervention indicated  Death  
Alanine 
aminotransferance  
increased  
Definition : A finding based 
on laboratory test results that 
indicate an increase in the 
level of ala nine 
aminotransferance (ALT or 
SGPT) in the blood 
specimen.  >ULN -3.[ADDRESS_662019]  >3.0-5.[ADDRESS_662020]  >5.0-20.[ADDRESS_662021]  >20.[ADDRESS_662022]  _ 
Aspartate 
aminotransferance  
increased  
Definition : A finding based 
on laboratory test results that 
indicate an increase in the 
level of alanine 
aminotransferance (ALT or  
SGPT) in the blood 
specimen.  >ULN -3.[ADDRESS_662023]  >3.0-5.[ADDRESS_662024]  >5.0-20.[ADDRESS_662025]  >20.[ADDRESS_662026]  _ 
Blood bilirubin 
increased  
Definition : A finding based 
on laboratory test results that 
indicate an increase in the 
level of aspartate 
aminotransferance (AST or 
SGOT) in the blood 
specimen.  >ULN -1.[ADDRESS_662027]  >1.5-3.[ADDRESS_662028]  >3.0-10.[ADDRESS_662029]  >10.[ADDRESS_662030]  _ 
 
 
 
 
 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 68 
Confidential  
 Cardiac Disorders  
 Grade  
Adverse Event  1 2 3 4 5 
Pleural effusion  
Definition : A disorder 
characterized by [CONTACT_511822]. Symptoms include 
shortness of breath, cough 
and market chest discomfort  Asymptomatic; clinical or 
diagnostic observations 
only; intervention not 
indicated  Symptomatic; intervention 
indicated (e.g. diuretics or 
limited therapeutic 
thoracentesis  Symptomatic with 
respi[INVESTIGATOR_450413]; surgical 
intervention including 
chest tube or pi[INVESTIGATOR_511786]-threatening 
respi[INVESTIGATOR_450412]; intubation or 
urgent intervention 
indicated  Death  
Pericardial effusion  
Definition : A disorder 
characterized by [CONTACT_511823], usually due 
to inflammation.  _ Asymptomatic e ffusion 
size small to moderate  Effusion with physiologic 
consequences  Life-threatening 
consequences; urgent 
intervention indicated  Death 
Edema face  
Definition : A disorder 
characterized by [CONTACT_511824].  Localized facial edema  
 Mode rated localized facial 
edema; limiting 
instrumental ADL  
 Severe swelling; limiting 
self care ADL  _ _ 
Edema limbs  
Definition : A disorder 
characterized  by [CONTACT_511825].  5-10% inter -limb 
discrepancy in volume or 
circumference at point of 
greatest visible difference; 
swelling or obscuration of 
anatomic architecture on 
close inspection  >10-30% inter -limb 
discrepancy in volume or 
circumference at point of 
greatest visible difference; 
readily apparent 
obscuration of anatomic 
architecture; obliteration 
of skin folds; readily 
apparent deviation from 
normal anatomic contour; 
limiting instrumental 
ADL  ≥30% inter -limb 
discrepancy in volume; 
gross deviation from 
normal anatomic contour, 
limiting self care ADL  _ _ 
Edema trunk  
Definition : A disorder 
characterized by [CONTACT_511826].  Swelling or obscuration of  
anatomic architecture on 
close inspection  Readily apparent 
obscuration of anatomic 
architecture; obliteration 
of skin folds; deadly 
apparent deviation from 
normal anatomic contour, 
limiting instrumental 
ADL  Gross deviation from 
normal anatomic contour; 
limiting self care ADL  _ _ 
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 69  
Confidential  
 Appendix VI. CYP3A4 drugs potentially affecting crenolanib pharmacokinetics  
 
The following are few examples of therapeutic agents which are potential hepatic enzyme (CYP3A4) 
inducing or inhibiting drugs and should be used with caution in  patient participation on the study):  
 
Strong Inducers  Strong Inhibitors  
phenytoin (anticonvulsants and mood stabilizers)  telithromycin (macrolide antibiotics)  
carbamazepi[INVESTIGATOR_050] (anticonvulsants and mood 
stabilizers)  clarithromycin (macrolide antibiotics)  
oxcarbazepi[INVESTIGATOR_050] (anticonvulsants and mood 
stabilizers)  ketoconazole (azole antifungals)  
phenobarbital (barbiturates)  itraconozole (azole antifungals)  
rifampin (bactericidal)  nefadozone (antidepressant)  
modafinil (stimulant)  
dexamethasone  Saquinavir (HIV protease inhibitor)  
hyperforin (constituent of St. John’s Wort)  Suoxone (analgesic)  
glucocorticoids  Telithromycin (antibiotic)  
Rifabutin (antimycobiotic)   
Troglitazone (anti -diabetic and anti -inflammatory 
drug)   
  
Moderate Inducers  Moderate Inhibitors  
pi[INVESTIGATOR_051] (Thiazolidinedione)  erythromycin (macrolide antibiotics)  
 fluconazole (azole antifungals)  
 aprepi[INVESTIGATOR_053] (antiemetic)  
 bergamottin (constituent of grapefruit 
juice)  
 verapamil (calcium channel blocker)  
 Diltiazem (calcium channel blocker)  
 
 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx  
 
  
PROTOCOL: ARO -006 Version 2 .0 January 4, 2017  
AROG PHARMACEUTICALS, INC.   Page 70  
Confidential  
 Appendix VII. The WHO  Classification of Acute Myeloid Leukemia [12] 
 
Name  [CONTACT_511831]:  
 AML with translocations between  chromosome 8  and 21 - 
[t(8;21)(q22;q22);]  RUNX1 /RUNX1T1 ;  
 AML with inversions in  chromosome 16  - [inv(16)(p13.1q22)] or internal translocations in it - 
[t(16;16)(p13.1;q22);]  CBFB /MYH11 ; (ICD -O 9871/3);  
 Acute promyelocytic leukemia  with translocations between  chromosome 15  and 17 - 
[t(15;17)(q22;q12);]  RARA /PML ; (ICD -O 9866/3);  
 AML with translocations between  chromosome 9  and 11 - [t(9;11)(p22;q23);]  MLLT3 /MLL ; 
 AML with translocations between  chromosome 6  and 9 - [t(6;9)(p23;q34);]  DEK /NUP214 ; 
 AML with inversions in  chromosome 3  - [inv(3)(q21q26.2)] or internal translocations in it - 
[t(3;3)(q21;q26.2);]  RPN1 /EVI1 ; 
 Megakaryoblastic AML with translocations between  chromosome 1  and 22 - 
[t(1;22)(p13;q13);]  RBM15 /MKL1 ; 
 AML with mutated  NPM1  
 AML with mutated  CEBPA  AML with myelodysplasia -related changes   
This category includes patients who have had a prior documented  myelodysplastic 
syndrome  (MDS) or  myeloproliferative disease  (MPD) that then has transformed into AML, or 
who have cytogenetic abnormalities characteristic for this type of AML (with previous history of 
MDS or MP D that has gone unnoticed in the past, but the cytogenetics is still suggestive of 
MDS/MPD history). This category of AML occurs most often in elderly patients and often has a 
worse prognosis.  
Includes:  
 AML with complex  karyotype  
 Unbalanced abnormalities  
 AML with deletions of  chromosome 7  - [del(7q);]  
 AML with deletions of  chromosome 5  - [del(5q);]  
 AML with unbalanced chromosomal aberrations in  chromosome 17  - [i(17q)/t(17p); ] 
 AML with deletions of  chromosome 13  - [del(13q);]  
 AML with deletions of  chromosome 11  - [del(11q); ] 
 AML with unbalanced chromosomal aberrations in  chromosome 12  - [del(12p)/t(12p);]  
 AML with deletions of  chromosome 9  - [del(9q);]  
 AML with aberrations in  chromosome X  - [idic(X)(q13);]  
 Balanced abnormalities  
 AML with translocations between  chromosome 11  and 16 - [t(11;16)(q23;q13.3);], 
unrelated to previous chemotherapy or ionizing radiatio n 
 AML with translocations between  chromosome 3  and 21 - [t(3;21)(q26.2;q22.1);], 
unrelated to previous  chemotherapy or ionizing radiation  
 AML with translocations between  chromosome 1  and 3 - [t(1;3)(p36.3;q 21.1);]  
 AML with translocations between  chromosome 2  and 11 - [t(2;11)(p21;q23);], unrelated 
to previo us chemotherapy or ionizing radiation  
 AML with translocations between  chromosome 5  and 12 - [t(5;12)(q33;p12);]  
 AML with translocations between  chromosome 5  and 7 - [t(5;7)(q33;q11.2);]  
 AML with t ranslocations between  chromosome 5  and 17 - [t(5;17)(q33;p13);]  
 AML with translocations between  chromosome 5  and 10 - [t(5;10)(q33;q21);]  
 AML with translocations between  chromosome 3  and 5 - [t(3;5)(q25;q34);]  
 
PROTOCOL: ARO -[ADDRESS_662031] had  prior chemotherapy and/or radiation and 
subsequently develop AML or MDS. These leukemias may be characterized by [CONTACT_511827], and often carry a worse prognosis.  AML not otherwise categorized  Includes subtypes of AML that do not fall into the above categories  
 AML with minimal differentiation  
 AML without maturation  
 AML with maturation  
 Acute myelomonocytic leukemia  
 Acute monoblastic and monocytic leukemia  
 Acute erythroid leukemia  
 Acute megakaryoblastic leukemia  
 Acute basophilic leukemia  
 Acute panmyelosis with myelofibrosi s 
 
PROTOCOL: ARO -[ADDRESS_662032] Information of Chief Medical Officer  
 
John Eckardt, MD  
AROG Pharmaceuticals, Inc.  
Email: jeckardt@arogpharma  
Phone: 214. 451.[ADDRESS_662033] Information of Director of Clinical Operations  
 
Abhijit Ramachandran  
AROG Pharmaceuticals, Inc.  
Email: [EMAIL_2552]  
Office: [PHONE_2865]  
Mobile: [PHONE_2866]  
Fax: [PHONE_2864]  
 
Contact [CONTACT_128940], Inc . 
Email:  vurity @arogpharma.com  
Office: [PHONE_10632]  
Fax: [PHONE_2864]  
 
Contact [CONTACT_511828], LLC  
Email: [EMAIL_2545]  
Office:  +[PHONE_2867]  
Fax: +[PHONE_2862]  
 
 